var title_f16_53_17232="Telomeric regions of chromosomes 4q and 10q";
var content_f16_53_17232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Telomeric regions of chromosomes 4q and 10q",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagrammatic representation of the hierarchical genetic organization of the telomeric regions of chromosomes 4q and 10q. Patients with facioscapulohumeral dystrophy have fewer than 10 copies of the D4Z4 repeat on chromosome 4, whereas 11 to 100 copies are normally present. The presence of a restriction site for BInI in the 10q repeats allows these two chromosomal repeats to be differentiated. Double digestion of genomic DNA with EcoRI and BInI eliminates the chromosome 10 EcoRI fragment containing D4Z4 repeats and thus allows measurement of size of the chromosome 4 EcoRI fragment, which results in almost 100 percent accurate diagnosis of FSHD.",
"    <div class=\"footnotes\">",
"     B: BInI; E: EcoRI; K: KpnI restriction sites; CEN: centromere; TEL: telomere.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orrell RW, Darras BT, Griggs RC. Facioscapulohumeral dystrophy, scapuloperoneal syndromes, and distal myopathies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones HR, De Vivo DC, Darras BT (Eds). Butterworth Heinemann, Philadelphia 2003. p.701. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17232=[""].join("\n");
var outline_f16_53_17232=null;
var title_f16_53_17233="Approach HTG pancreatitis";
var content_f16_53_17233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Proposed approach to hypertriglyceridemic pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 595px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from: Macmillan Publishers Ltd. Tsuang W, Navaneethan U, Ruiz L, et al. Hypertriglyceridemic pancreatitis: Presentation and management. Am J Gastroenterol 2009; 104:984. Copyright &copy; 2009.",
"     <a href=\"file://www.nature.com/ajg/\" style=\"font-style: italic;\" target=\"_blank\">",
"      www.nature.com/ajg/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17233=[""].join("\n");
var outline_f16_53_17233=null;
var title_f16_53_17234="Patient information: Sinusitis in adults (The Basics)";
var content_f16_53_17234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15535\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/62/10210\">",
"         Sinuses of the face",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/18/16674\">",
"         Patient information: Rinsing out your nose with salt water (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/13/37073\">",
"         Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/58/42915\">",
"         Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40643\">",
"         Patient information: The common cold in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sinusitis in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sinusitis-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H566815693\">",
"      <span class=\"h1\">",
"       What is sinusitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sinusitis is a condition that can cause a stuffy nose, pain in the face, and yellow or green discharge (mucus) from the nose. The sinuses are hollow areas in the bones of the face (",
"      <a class=\"graphic graphic_figure graphicRef75045 \" href=\"UTD.htm?9/62/10210\">",
"       figure 1",
"      </a>",
"      ). They have a thin lining that normally makes a small amount of mucus. When this lining gets infected, it swells and makes extra mucus. This causes symptoms.",
"     </p>",
"     <p>",
"      Sinusitis can occur when a person gets sick with a cold. The germs causing the cold can also infect the sinuses. Many times, a person feels like his or her cold is getting better. But then he or she gets sinusitis and begins to feel sick again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H566815700\">",
"      <span class=\"h1\">",
"       What are the symptoms of sinusitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms of sinusitis include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Stuffy or blocked nose",
"       </li>",
"       <li>",
"        Thick yellow or green discharge from the nose",
"       </li>",
"       <li>",
"        Pain in the teeth",
"       </li>",
"       <li>",
"        Pain or pressure in the face &ndash; This often feels worse when a person bends forward.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with sinusitis can also have other symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Trouble smelling",
"       </li>",
"       <li>",
"        Ear pressure or fullness",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Bad breath",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most of the time, symptoms start to improve in 7 to 10 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H566815707\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if your symptoms last more than 7 days, or if your symptoms get better at first but then get worse.",
"     </p>",
"     <p>",
"      Sometimes, sinusitis can lead to serious problems. See your doctor or nurse right away (do not wait 7 days) if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever higher than 102.5&deg;F (39.2&deg;C)",
"       </li>",
"       <li>",
"        Sudden and severe pain in the face and head",
"       </li>",
"       <li>",
"        Trouble seeing or seeing double",
"       </li>",
"       <li>",
"        Trouble thinking clearly",
"       </li>",
"       <li>",
"        Swelling or redness around one or both eyes",
"       </li>",
"       <li>",
"        Trouble breathing or a stiff neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H566815714\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To reduce your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take an over the counter pain reliever to reduce the pain",
"       </li>",
"       <li>",
"        Rinse your nose and sinuses with salt water a few times a day &ndash; Ask your doctor or nurse about the best way to do this.",
"       </li>",
"       <li>",
"        Use a decongestant nose spray &ndash; These sprays are sold in a pharmacy. But do not use decongestant nose sprays for more than 2 to 3 days in a row. Using them more than 3 days in a row can make symptoms worse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might also prescribe a steroid nose spray to reduce the swelling in your nose. (Steroid nose sprays do not contain the same steroids that athletes take to build muscle.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H566815721\">",
"      <span class=\"h1\">",
"       How is sinusitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, sinusitis does not need to be treated with antibiotic medicines. This is because most sinusitis is caused by viruses &mdash; not bacteria &mdash; and antibiotics do not kill viruses. Many people get over sinus infections without antibiotics.",
"     </p>",
"     <p>",
"      Some people with sinusitis do need treatment with antibiotics. If your symptoms have not improved after 7 to 10 days, ask your doctor if you should take antibiotics. Your doctor might recommend that you wait one more week to see if your symptoms improve. But if you have symptoms such as a fever or a lot of pain, he or she might prescribe antibiotics. It is important to follow your doctor&rsquo;s instructions about taking your antibiotics.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H566815728\">",
"      <span class=\"h1\">",
"       What if my symptoms do not get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms do not get better, talk with your doctor or nurse. He or she might order tests to figure out why you still have symptoms. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        CT scan or other imaging tests &ndash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A test to look inside the sinuses &ndash; For this test, a doctor puts a thin tube with a camera on the end into the nose and up into the sinuses.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people get a lot of sinus infections or have symptoms that last at least 3 months. These people can have a different type of sinusitis called &ldquo;chronic sinusitis.&rdquo; Chronic sinusitis can be caused by different things. For example, some people have growths in their nose or sinuses that are called &ldquo;polyps.&rdquo; Other people have allergies that cause their symptoms.",
"     </p>",
"     <p>",
"      Chronic sinusitis can be treated in different ways. If you have chronic sinusitis, talk with your doctor about which treatments are right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H566815735\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/13/37073?source=see_link\">",
"       Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"       Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=see_link\">",
"       Patient information: The common cold in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/18/16674?source=see_link\">",
"       Patient information: Rinsing out your nose with salt water (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/53/17234?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15535 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17234=[""].join("\n");
var outline_f16_53_17234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815693\">",
"      What is sinusitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815700\">",
"      What are the symptoms of sinusitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815707\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815714\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815721\">",
"      How is sinusitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815728\">",
"      What if my symptoms do not get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H566815735\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/62/10210\">",
"      Sinuses of the face",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/13/37073?source=related_link\">",
"      Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=related_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/18/16674?source=related_link\">",
"      Patient information: Rinsing out your nose with salt water (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17235="Cocaine purpura on extremity";
var content_f16_53_17235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cocaine levamisole toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retiform purpura with bullae are present on the leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17235=[""].join("\n");
var outline_f16_53_17235=null;
var title_f16_53_17236="Multiple vitamins (prenatal): Patient drug information";
var content_f16_53_17236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Multiple vitamins (prenatal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/26/4516?source=see_link\">",
"     see \"Multiple vitamins (prenatal): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Free Prenatal [OTC];",
"     </li>",
"     <li>",
"      CitraNatal&reg; Harmony&trade;;",
"     </li>",
"     <li>",
"      CitraNatal&trade; 90 DHA;",
"     </li>",
"     <li>",
"      CitraNatal&trade; Assure;",
"     </li>",
"     <li>",
"      CitraNatal&trade; B-Calm;",
"     </li>",
"     <li>",
"      CitraNatal&trade; DHA;",
"     </li>",
"     <li>",
"      CitraNatal&trade; Rx;",
"     </li>",
"     <li>",
"      Concept DHA&trade;;",
"     </li>",
"     <li>",
"      Concept OB&trade;;",
"     </li>",
"     <li>",
"      Duet&reg;;",
"     </li>",
"     <li>",
"      Duet&reg; Balanced DHA",
"      <sup>",
"       ec",
"      </sup>",
"     </li>",
"     <li>",
"      Femecal OB;",
"     </li>",
"     <li>",
"      Folcaps&trade; Care One;",
"     </li>",
"     <li>",
"      Foltabs&trade; Prenatal;",
"     </li>",
"     <li>",
"      Foltabs&trade; Prenatal Plus DHA;",
"     </li>",
"     <li>",
"      Gesticare&reg; DHA;",
"     </li>",
"     <li>",
"      KPN Prenatal [OTC];",
"     </li>",
"     <li>",
"      Mini-Prenatal [OTC];",
"     </li>",
"     <li>",
"      Multi-Nate 30;",
"     </li>",
"     <li>",
"      NataFort&reg; [OTC];",
"     </li>",
"     <li>",
"      N&eacute;evo&reg;;",
"     </li>",
"     <li>",
"      N&eacute;evo&reg; DHA;",
"     </li>",
"     <li>",
"      One A Day&reg; Women&rsquo;s Prenatal [OTC];",
"     </li>",
"     <li>",
"      OptiNate&reg;;",
"     </li>",
"     <li>",
"      Paire OB&trade; Plus DHA;",
"     </li>",
"     <li>",
"      PreCare&reg;;",
"     </li>",
"     <li>",
"      PreferaOB&reg;;",
"     </li>",
"     <li>",
"      PreferaOB&reg; + DHA;",
"     </li>",
"     <li>",
"      PreferaOB&reg; One&trade;;",
"     </li>",
"     <li>",
"      Prenatabs FA;",
"     </li>",
"     <li>",
"      Prenatal One Daily [OTC];",
"     </li>",
"     <li>",
"      Prenatal Rx 1;",
"     </li>",
"     <li>",
"      Prenatal With Beta Carotene [OTC];",
"     </li>",
"     <li>",
"      Prenate DHA&trade;;",
"     </li>",
"     <li>",
"      Prenate Elite&reg;;",
"     </li>",
"     <li>",
"      Prenate Essential&trade;;",
"     </li>",
"     <li>",
"      PreNexa&reg; Premier;",
"     </li>",
"     <li>",
"      PrimaCare&reg; One;",
"     </li>",
"     <li>",
"      Select-OB&trade;;",
"     </li>",
"     <li>",
"      Stuart Prenatal&reg; [OTC];",
"     </li>",
"     <li>",
"      Tandem&reg; DHA;",
"     </li>",
"     <li>",
"      Tandem&reg; OB;",
"     </li>",
"     <li>",
"      TriCare&reg; Prenatal;",
"     </li>",
"     <li>",
"      TriCare&reg; Prenatal DHA One&reg;;",
"     </li>",
"     <li>",
"      Vinacal&trade;;",
"     </li>",
"     <li>",
"      Vinate&reg; Care;",
"     </li>",
"     <li>",
"      Vitafol&reg;-OB [OTC];",
"     </li>",
"     <li>",
"      Vitafol&reg;-OB+DHA [OTC];",
"     </li>",
"     <li>",
"      Vitafol&reg;-PN;",
"     </li>",
"     <li>",
"      VitaPhil + DHA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13817351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Accidental overdose of drugs that have iron in them is a leading cause of deadly poisoning in children younger than 6 years of age. Keep away from children. If this drug is taken by accident, call a doctor or poison control center right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This vitamin is used to aid the diet needs of a pregnant woman or one trying to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697123",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a baby with a birth defect, talk with your doctor before trying to get pregnant. You may need even higher doses of folic acid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Want to stop taking prenatal multivitamin, mostly during first 12 weeks of your pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this vitamin with or without food. Take with food or at bedtime if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are in your first 12 weeks of your pregnancy, you may want to take a prenatal vitamin without extra iron. Iron may cause hard stools (constipation) and upset stomach. Extra iron is most often needed in the second and third trimesters.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11145 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-93FDCDF71C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17236=[""].join("\n");
var outline_f16_53_17236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817351\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013383\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013382\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013387\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013388\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013390\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013385\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013386\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013391\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013392\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/26/4516?source=related_link\">",
"      Multiple vitamins (prenatal): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17237="Minocycline: Patient drug information";
var content_f16_53_17237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Minocycline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     see \"Minocycline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=see_link\">",
"     see \"Minocycline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dynacin&reg;;",
"     </li>",
"     <li>",
"      Minocin&reg;;",
"     </li>",
"     <li>",
"      Minocin&reg; PAC;",
"     </li>",
"     <li>",
"      Solodyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Minocycline&reg;;",
"     </li>",
"     <li>",
"      Arestin Microspheres;",
"     </li>",
"     <li>",
"      Dom-Minocycline;",
"     </li>",
"     <li>",
"      Minocin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Minocycline;",
"     </li>",
"     <li>",
"      Novo-Minocycline;",
"     </li>",
"     <li>",
"      PHL-Minocycline;",
"     </li>",
"     <li>",
"      PMS-Minocycline;",
"     </li>",
"     <li>",
"      ratio-Minocycline;",
"     </li>",
"     <li>",
"      Riva-Minocycline;",
"     </li>",
"     <li>",
"      Sandoz-Minocycline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to minocycline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take bismuth (Pepto-Bismol&reg;), calcium, iron, magnesium, zinc, multivitamins with minerals, colestipol, cholestyramine, didanosine, or antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not lie down for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablet: Swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10870 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-FD66CD12EC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17237=[""].join("\n");
var outline_f16_53_17237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025421\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025423\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025422\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025427\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025428\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025430\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025425\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025426\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025431\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025432\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=related_link\">",
"      Minocycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=related_link\">",
"      Minocycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17238="Hamartoma with cartilage";
var content_f16_53_17238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hamartoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows a predominance of cartilagenous tissue. The cleft-like space on the left of the image is lined with cuboidal respiratory epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17238=[""].join("\n");
var outline_f16_53_17238=null;
var title_f16_53_17239="Retinitis pigmentosa: Treatment";
var content_f16_53_17239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinitis pigmentosa: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17239/contributors\">",
"     Seema Garg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17239/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17239/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/53/17239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinitis pigmentosa (RP) comprises a complex group of inherited dystrophies characterized by progressive degeneration and dysfunction of the retina, primarily affecting photoreceptor and pigment epithelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical manifestations of retinitis pigmentosa (RP) include night blindness, loss of peripheral vision from progressive loss of photoreceptors, and variably loss of central vision due to cataracts and macular edema.",
"   </p>",
"   <p>",
"    Although there is no cure for RP, treatments are available for managing some aspects of its clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/2\">",
"     2",
"    </a>",
"    ]. New treatments, involving gene therapy, transplantation, and implanted electrical devices, are in active development.",
"   </p>",
"   <p>",
"    This topic will address currently available treatment options, as well as review therapeutic strategies that remain experimental. The clinical manifestations and diagnosis of retinitis pigmentosa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=see_link\">",
"     \"Retinitis pigmentosa: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MODULATING PHOTORECEPTOR LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin and nutritional supplementation therapy, while currently available, is beneficial only for a limited group of patients with some forms of RP. Several new treatments are on the horizon to slow or possibly even reverse the retinal degeneration caused by photoreceptor loss. These treatments include gene therapy and retinal cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vitamin and nutritional supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for vitamin therapy in RP was originally suggested by an observational study in which patients with RP who were taking vitamins A and E appeared to have slower decline in electroretinography (ERG) measurements than those not taking vitamin supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary modification is the definitive therapy for three rare forms of retinitis pigmentosa:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abetalipoproteinemia (Bassen-Kornzweig syndrome) &mdash; Abetalipoproteinemia is a genetic disorder that causes defective intestinal absorption of lipids, including fat soluble vitamins. Ophthalmologic and neurologic manifestations of abetalipoproteinemia include RP, peripheral neuropathy, ataxia, and, in up to one-third of patients, mental retardation. Treatment with fat soluble vitamins (E, A, and K) can modify manifestations of the disease. In early stages of disease, vitamin A and E supplementation may restore retinal function, improving dark adaptation and reversing ERG abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H10#H10\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Abetalipoproteinemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phytanic acid oxidase deficiency (Refsum disease) &mdash; Refsum disease is the result of a genetic abnormality in which the enzyme that breaks down phytanic acid is absent. Patients develop RP, cerebellar ataxia, and peripheral polyneuropathy. Severely reducing intake of foods containing phytanic acid, such as dairy products, certain types of meat, and seafood, can slow or stop progression of the disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H13#H13\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Refsum disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alpha-tocopherol transport protein deficiency (ataxia with vitamin E deficiency) &mdash; Alpha-tocopherol transport protein deficiency is a hereditary syndrome with RP, ataxia, and vitamin E deficiency. Treatment with vitamin E may halt progression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of the hereditary ataxias\", section on 'Treatable diseases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role for vitamin A in the treatment for RP, outside of its well-established indication in patients with abetalipoproteinemia, remains controversial.",
"   </p>",
"   <p>",
"    In a randomized controlled trial, 601 patients aged 18 to 49 years with RP (including autosomal dominant, autosomal recessive, X-linked non-syndromic and Usher syndrome) were randomly assigned to one of four treatment groups: vitamin A (15,000",
"    <span class=\"nowrap\">",
"     IU/day);",
"    </span>",
"    vitamin E (400",
"    <span class=\"nowrap\">",
"     IU/day);",
"    </span>",
"    both vitamin A and E at these doses; or trace amounts of vitamin A and E [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/7\">",
"     7",
"    </a>",
"    ]. Cone electroretinogram (ERG) amplitudes were measured. At four to six year follow-up, patients taking supplemental vitamin A had a slightly lower rate of decline of ERG amplitudes. Results suggested that vitamin E had a negative impact, accelerating the decline of ERG amplitudes in a subset of patients with the highest initial cone ERG results. No significant effect on visual field or visual acuity was noted for either vitamin supplement.",
"   </p>",
"   <p>",
"    The study design was robust, but there are several limitations in drawing conclusions about the beneficial effects of vitamin A. Positive response to treatment was seen only on the ERG, and no effect was seen on clinically relevant measures of visual function such as visual acuity or visual field. Additionally, these results have not been repeated and remain unconfirmed. Finally, there is a theoretical risk of toxicity from long-term high-dose vitamin A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    .) The toxic effects of high dose vitamin A include hepatomegaly, bone changes such as osteoporosis, elevated blood lipid levels, increased intracranial pressure and teratogenicity. Although the daily intake of the dose of vitamin A palmitate suggested as treatment for retinitis pigmentosa (15,000 IU, equivalent to three times the daily allowance) was not shown to be harmful in adults in this study, there are no well-controlled studies on the effect of vitamin A at this dose when taken longer term, such as decades.",
"   </p>",
"   <p>",
"    It remains controversial whether the small potential benefits of vitamin A supplementation outweigh the potential risks. Therefore, we do not recommend high dose vitamin A for patients with RP. However, we do suggest that adults with early to middle stages of retinitis pigmentosa avoid vitamin E supplements.",
"   </p>",
"   <p>",
"    Patients who have been advised to take vitamin A should have annual fasting vitamin A levels and liver function tests; older patients should be monitored for osteoporosis. High dose vitamin A supplementation is contraindicated during pregnancy or for those planning to become pregnant, due to teratogenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Omega-3 fatty acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHA (docosahexaenoic acid), an omega-3 fatty acid found naturally in fish, is a major structural lipid of retinal photoreceptor outer segment membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/8\">",
"     8",
"    </a>",
"    ] and may be involved in rhodopsin regeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two randomized trials, one in patients with X-linked RP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/10\">",
"     10",
"    </a>",
"    ] and one in patients with RP who were also receiving high dose vitamin A [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/11\">",
"     11",
"    </a>",
"    ], failed to demonstrate an effect of oral DHA on changes in visual field, visual acuity, or cone ERG. However, in subgroup analyses from these trials, subjects with the highest red blood cell concentrations of DHA (combining patients who received supplements as well as controls who had diets high in fish oils) had the slowest rates of retinal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. An observational study of 357 patients with RP who were participating in randomized trials of vitamin A found a 40 percent slower rate of annual decline in distance visual acuity for those whose food questionnaire indicated a diet high in omega-3 fatty acids (&gt;0.20",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/13\">",
"     13",
"    </a>",
"    ]. A systematic review of six studies, not all randomized, found trends suggesting improved outcomes with use of omega-3 fatty acid supplements, but recommended additional studies before concluding definitive benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Experimental therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While still in the experimental phase, several emerging technologies may provide hope for therapeutic options in the future for RP patients. Approximately 50 clinical trials are listed for retinitis pigmentosa in 2012 with several in progress (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     file://clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remarkable progress in the past two decades has led to the identification of over 50 genes involved in RP. These discoveries have spearheaded research into gene therapies. Where genetic defects lead to the loss of an encoded protein, gene-replacement therapy could potentially induce production of the missing protein. As an example, the first successful gene therapy for retinal degenerative disease in a large animal was demonstrated in a canine model of Leber congenital amaurosis (LCA), a form of RP present at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with LCA have a mutation in RPE65 that prevents the production of an essential photopigment, 11-cis retinal. A functional gene for the photopigment was produced using an adenovirus vector; subretinal injection of the modified DNA into the dog's eye resulted in incorporation of the functional gene in the retinal pigment epithelial cell and 11-cis retinal production. In a gene therapy trial in a dog model, researchers successfully treated dogs with two different RPGR mutations that cause XLRP in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/16\">",
"     16",
"    </a>",
"    ]. The similarities between humans and dogs, in terms of eye anatomy, physiology, disease characteristics, and positive response to this gene therapy raise hope for a path to human therapies.",
"   </p>",
"   <p>",
"    Initial human gene therapy trials for LCA have been undertaken with encouraging preliminary safety and efficacy findings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Phase 1 studies in humans with LCA have been reported, assessing the short-term safety of gene transfer by subretinal injection, using an adeno-associated virus (AAV) combined with the RPE65 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The largest study involved 12 patients, aged 8 to 44 years, and three different vector doses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/18\">",
"     18",
"    </a>",
"    ]. All patients reported subjective visual improvement in dimly lit rooms; 7 patients demonstrated objective improvement in visual acuity which was not dose-related. Visual fields and pupillary light responses improved in all patients. Four children demonstrated significantly improved ability to navigate an obstacle. Younger patients had better visual function at baseline but also demonstrated the greatest overall improvement in visual function. Benefits were sustained at two-year follow-up, and there were no adverse effects other than transient foveal dehiscence in one patient. Viral vector was demonstrable in the bloodstream in two patients suggesting a dose limit for virus exposure in future treatment protocols.",
"   </p>",
"   <p>",
"    These encouraging results indicate need for larger trials with longer term follow-up, perhaps involving patients with less advanced degeneration and a greater chance of vision response. Timing of gene replacement in the progression of RP may be critical, as viable photoreceptor cells must still be present in enough numbers to respond to the missing protein and restore visual function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Retinal cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for transplanted retinas, retinal sheets, and clumps of retinal neurons to restore vision in mice and humans with RP has been under investigation since the 1980s. Until recently, transplanted tissue or cells have not developed synaptic connections with host cells and thus have not had functional impact [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential for transplantation of fetal retinal pigment epithelium to rescue abnormal photoreceptors in RP is being investigated. After fetal retinal implantation into six patients with RP, slight improvement in visual acuity was seen in three patients (one patient with bilateral improvement including the eye that did not receive the transplant) although the extent of improvement was not clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/24\">",
"     24",
"    </a>",
"    ]. Integration of donor cells into the host retina is dependent upon the stage of cell differentiation at the time of donor harvest [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/25\">",
"     25",
"    </a>",
"    ]. Successful integration of committed fetal progenitor cells that developed into functional rod photoreceptors was demonstrated in a mouse model of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/25\">",
"     25",
"    </a>",
"    ]. Transplanted cells did not integrate into the retina in mice with more active disease and more rapid retinal degeneration.",
"   </p>",
"   <p>",
"    Regulatory and ethical issues with use of human fetal retinal cells has led to exploration of human embryonic stem cells that might be induced to differentiate into photoreceptor progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/26\">",
"     26",
"    </a>",
"    ]. Such stem cells may also produce factors that enhance survival of host photoreceptors, as demonstrated in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In addition, mouse embryonic stem cells can be used to create a complex three-dimensional array of retinal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/29\">",
"     29",
"    </a>",
"    ], which in the future may be transplanted into patients with retinitis pigmentosa.",
"   </p>",
"   <p>",
"    A human clinical trial, the Safety Study in Retinal Transplantation for Retinitis Pigmentosa, has completed enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/30\">",
"     30",
"    </a>",
"    ]. Its long-term goal is to determine if transplantation can prevent blindness or restore eyesight in patients with retinitis pigmentosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Retinal prosthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices are being tested that transduce light into electrical signals and transmit this information directly to the inner retina (bypassing the diseased outer retina of RP), optic nerve, or occipital visual cortex. Patients involved in studies of these devices have reported seeing flashes of light and have been able to sense motion, locate large objects, and recognize large letters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One retinal prosthesis system (Argus II) converts video images captured from a very small camera housed in the patient&rsquo;s glasses, into a series of small electrical impulses that are wirelessly transmitted to an array of 60 electrodes on the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/34\">",
"     34",
"    </a>",
"    ]. Argus II was approved for use in Europe in 2011 and is undergoing review by the US Food and Drug Administration in 2012. Newer generations of prostheses have increasingly more electrodes, with one in the development phase with over 1000 electrodes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/35\">",
"     35",
"    </a>",
"    ]. Retinal prostheses have the potential to enhance the quality of life of RP patients by aiding in object recognition, mobility, and independent living.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362778889\">",
"    <span class=\"h3\">",
"     Oral retinoid treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An oral retinoid medication, QLT091001, bypasses the biochemical blockade of the retinoid cycle caused by RPE65 and LRAT mutations and is in early investigational stages. Preliminary data from a phase 1b trial in 17 individuals indicate some improvement in visual field size and visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Macular edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoid macular edema can reduce central vision in later stages of RP. The most successful treatment thus far is the oral carbonic anhydrase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    . Acetazolamide increases fluid absorption across the retinal pigment epithelium. In the absence of macular edema, carbonic anhydrase inhibitors do not improve vision or alter the course of electroretinography (ERG) degradation in patients with RP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small crossover trial, 10 of 12 patients with RP and chronic macular edema demonstrated objective and subjective improvement in visual acuity when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    500 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/38\">",
"     38",
"    </a>",
"    ]. Side effects include peripheral paresthesias, loss of appetite, fatigue, renal stones, and anemia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41652?source=see_link\">",
"     Methazolamide",
"    </a>",
"    has fewer side effects, but may be less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/39\">",
"     39",
"    </a>",
"    ]. Rebound edema has been reported due to tachyphylaxis to oral carbonic anhydrases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/30/23012?source=see_link\">",
"     Dorzolamide",
"    </a>",
"    , a topical carbonic anhydrase, may be effective for patients who cannot tolerate the systemic effects of oral carbonic anhydrases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/42\">",
"     42",
"    </a>",
"    ]. In a retrospective cohort study of 32 patients with cystoid macular edema from RP and Usher syndrome who received dorzolamide, ten patients (31 percent) had improved visual acuity by &ge;7 letters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports of the use of intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    in patients with RP and macular edema describe a limited and transient response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Large randomized trials have not been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cataract extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior subcapsular cataracts develop in 35 to 51 percent of adult patients with RP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Central vision may improve with cataract extraction. However, patients must be counseled that there will be no improvement in their visual field and no impact on progression of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Light restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although reduced light exposure decreased the rate of photoreceptor loss in two animal models of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], there are no data in humans to support advising patients to limit their exposure to light. Two case studies, involving patients with RP who had restricted light exposure to one eye but not the other, found no difference in ERG results or ophthalmoscopic appearance between the eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17239/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/28/4546?source=see_link\">",
"       \"Patient information: Retinitis pigmentosa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no cure for the photoreceptor loss or retinal epithelial damage associated with simple retinitis pigmentosa (RP). Some rare forms of RP, associated with multiorgan involvement, are due to specific nutritional deficiencies and may respond to dietary modification or vitamin supplementation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Vitamin and nutritional supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-dose vitamin A supplementation may slow the rate of decline of the amplitude of the cone photoreceptor ERG response, but has not been shown to slow loss of vision. Except for patients with abetalipoproteinemia, we suggest not treating patients with high-dose vitamin A (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Except for patients with rare syndromes of RP related to vitamin E deficiency, we suggest patients with RP not take supplemental vitamin E (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Vitamin A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term effectiveness of docosahexaenoic acid (DHA), an omega-3 fatty acid, on progression of RP is uncertain. No benefit was demonstrated in a randomized trial, although observational studies have shown possible benefit. Until results are available from additional trials, we suggest that patients with RP consume a diet high in omega 3 fatty acids, but we suggest that patients do not take supplemental DHA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Omega-3 fatty acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Experimental approaches to treatment for RP, under active investigation, include gene therapy, transplantation of fetal retinal cells or stem cells, and electronic retinal prostheses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Experimental therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with macular edema and RP be treated with an oral carbonic anhydrase inhibitor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Macular edema'",
"      </a>",
"      above.) A topical carbonic anhydrase inhibitor is an alternative in patients who do not tolerate the oral formulation.",
"     </li>",
"     <li>",
"      Patients with RP and posterior cataracts will likely benefit from cataract extraction. There is no evidence that reduced light exposure provides benefit for RP patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other treatments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/1\">",
"      Retinitis pigmentosa. A symposium on terminology and methods of examination. Ophthalmology 1983; 90:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/2\">",
"      Jacobson SG, Cideciyan AV. Treatment possibilities for retinitis pigmentosa. N Engl J Med 2010; 363:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/3\">",
"      Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 1993; 34:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/4\">",
"      Gouras P, Carr RE, Gunkel RD. Retinitis pigmentosa in abetalipoproteinemia: Effects of vitamin A. Invest Ophthalmol 1971; 10:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/5\">",
"      Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000; 40:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/6\">",
"      Bieri JG, Hoeg JM, Schaefer EJ, et al. Vitamin A and vitamin E replacement in abetalipoproteinemia. Ann Intern Med 1984; 100:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/7\">",
"      Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993; 111:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/8\">",
"      Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/9\">",
"      Chen Y, Houghton LA, Brenna JT, Noy N. Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoid-binding protein with 11-cis-retinal. J Biol Chem 1996; 271:20507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/10\">",
"      Hoffman DR, Locke KG, Wheaton DH, et al. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004; 137:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/11\">",
"      Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004; 122:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/12\">",
"      Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol 2004; 122:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/13\">",
"      Berson EL, Rosner B, Sandberg MA, et al. &omega;-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2012; 130:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/14\">",
"      Hodge WG, Barnes D, Schachter HM, et al. The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review. Can J Ophthalmol 2006; 41:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/15\">",
"      Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/16\">",
"      Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A 2012; 109:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/17\">",
"      Chung DC, Lee V, Maguire AM. Recent advances in ocular gene therapy. Curr Opin Ophthalmol 2009; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/18\">",
"      Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/19\">",
"      Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/20\">",
"      Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/21\">",
"      Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008; 105:15112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/22\">",
"      Bennett J. Retinal progenitor cells--timing is everything. N Engl J Med 2007; 356:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/23\">",
"      Berger AS, Tezel TH, Del Priore LV, Kaplan HJ. Photoreceptor transplantation in retinitis pigmentosa: short-term follow-up. Ophthalmology 2003; 110:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/24\">",
"      Radtke ND, Aramant RB, Petry HM, et al. Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium. Am J Ophthalmol 2008; 146:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/25\">",
"      MacLaren RE, Pearson RA, MacNeil A, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006; 444:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/26\">",
"      Lamba DA, Karl MO, Ware CB, Reh TA. Efficient generation of retinal progenitor cells from human embryonic stem cells. Proc Natl Acad Sci U S A 2006; 103:12769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/27\">",
"      Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cells 2006; 24:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/28\">",
"      Smith LE. Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa. J Clin Invest 2004; 114:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/29\">",
"      Eiraku M, Takata N, Ishibashi H, et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 2011; 472:51.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00345917 (Accessed on November 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/31\">",
"      Chow AY, Chow VY, Packo KH, et al. The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol 2004; 122:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/32\">",
"      Humayun MS, Weiland JD, Fujii GY, et al. Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vision Res 2003; 43:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/33\">",
"      Yanai D, Weiland JD, Mahadevappa M, et al. Visual performance using a retinal prosthesis in three subjects with retinitis pigmentosa. Am J Ophthalmol 2007; 143:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/34\">",
"      Ahuja AK, Dorn JD, Caspi A, et al. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol 2011; 95:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/35\">",
"      Chader GJ, Weiland J, Humayun MS. Artificial vision: needs, functioning, and testing of a retinal electronic prosthesis. Prog Brain Res 2009; 175:317.",
"     </a>",
"    </li>",
"    <li>",
"     Scholl H. Increased vision with QLT091001 in blindness due to mutations in retinal pigment epithilium-specific protein 65kDa (RPE65) or lecithin retinol Acyltransferase (LRAT). Retina Society: 45th Annual Scientific Meeting. October 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/37\">",
"      Greenstein VC, Holopigian K, Siderides E, et al. The effects of acetazolamide on visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1993; 34:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/38\">",
"      Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 1989; 107:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/39\">",
"      Fishman GA, Gilbert LD, Anderson RJ, et al. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology 1994; 101:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/40\">",
"      Fishman GA, Glenn AM, Gilbert LD. Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa. Arch Ophthalmol 1993; 111:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/41\">",
"      Apushkin MA, Fishman GA, Grover S, Janowicz MJ. Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 2007; 27:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/42\">",
"      Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2007; 91:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/43\">",
"      Genead MA, Fishman GA. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Arch Ophthalmol 2010; 128:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/44\">",
"      Minnella AM, Falsini B, Bamonte G, et al. Optical coherence tomography and focal electroretinogram evaluation of cystoid macular edema secondary to retinitis pigmentosa treated with intravitreal triamcinolone: case report. Eur J Ophthalmol 2006; 16:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/45\">",
"      Scorolli L, Morara M, Meduri A, et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 2007; 125:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/46\">",
"      Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol 1982; 93:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/47\">",
"      Bastek JV, Heckenlively JR, Straatsma BR. Cataract surgery in retinitis pigmentosa patients. Ophthalmology 1982; 89:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/48\">",
"      Fishman GA, Anderson RJ, Lourenco P. Prevalence of posterior subcapsular lens opacities in patients with retinitis pigmentosa. Br J Ophthalmol 1985; 69:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/49\">",
"      Naash ML, Peachey NS, Li ZY, et al. Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. Invest Ophthalmol Vis Sci 1996; 37:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/50\">",
"      Cideciyan AV, Jacobson SG, Aleman TS, et al. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci U S A 2005; 102:5233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/51\">",
"      Berson EL. Light deprivation and retinitis pigmentosa. Vision Res 1980; 20:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17239/abstract/52\">",
"      Miyake Y, Sugita S, Horiguchi M, Yagasaki K. Light deprivation and retinitis pigmentosa. Am J Ophthalmol 1990; 110:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6911 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-207A0925F2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17239=[""].join("\n");
var outline_f16_53_17239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MODULATING PHOTORECEPTOR LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vitamin and nutritional supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Omega-3 fatty acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Experimental therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Retinal cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Retinal prosthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362778889\">",
"      - Oral retinoid treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Macular edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cataract extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Light restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/28/4546?source=related_link\">",
"      Patient information: Retinitis pigmentosa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=related_link\">",
"      Retinitis pigmentosa: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17240="Prevention and management of growth failure in children with chronic kidney disease";
var content_f16_53_17240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and management of growth failure in children with chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17240/contributors\">",
"     Burkhard T&ouml;nshoff, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17240/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17240/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/53/17240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H359700116\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth retardation is a major complication of children with chronic kidney disease (CKD). Poor growth is a marker of disease severity and is associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention and management of growth impairment in children with CKD and after renal transplantation will be reviewed here. The impact, risk factors, and underlying pathogenesis of growth impairment in children with CKD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359700212\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359700220\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition and classification of chronic kidney disease (CKD) guidelines were introduced by the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    in 2002. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Definitions and classifications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup developed a classification system for patients greater than two years of age based upon the level of kidney function, which is independent of the primary renal diagnosis (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    ). This staging system was aimed at promoting early detection and treatment of CKD. The stages and their definitions based upon estimated glomerular filtration rate (GFR) are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 disease &ndash; Normal GFR (&ge;90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Stage 2 disease &ndash; GFR between 60 to 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 3 disease &ndash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 4 disease &ndash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 5 disease &ndash; GFR of less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or end-stage renal disease (ESRD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359700228\">",
"    <span class=\"h2\">",
"     Growth measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Z score for growth is a conversion of",
"    <span class=\"nowrap\">",
"     height/length",
"    </span>",
"    that represents the number of standard deviations from the mean height values for age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H5#H5\">",
"     \"Measurement of growth in children\", section on 'Z-scores'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697767\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention and management of growth impairment in children with chronic kidney disease (CKD) are based on avoiding and correcting the following factors that contribute to poor growth (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H113914234#H113914234\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Pathogenesis: Disturbance of GH/IGF-I axis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H11319607#H11319607\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Risk factors that contribute to impaired growth'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate nutrition",
"     </li>",
"     <li>",
"      Fluid and electrolyte abnormalities including metabolic acidosis",
"     </li>",
"     <li>",
"      Renal osteodystrophy",
"     </li>",
"     <li>",
"      Disturbances of the growth hormone (GH) and insulin-like growth factor-I (IGF-I) axis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management approach consists of a combination of the following interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive measures are directed toward preventing or correcting amenable complications of CKD, including malnutrition, metabolic acidosis, fluid and electrolyte abnormalities, and renal osteodystrophy.",
"     </li>",
"     <li>",
"      Renal replacement therapy (RRT) is generally initiated in children with stage 5 CKD and who have uremic symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metabolic abnormalities that are refractory to medical management, and facilitate fluid management and ensure adequate nutrition. Renal transplantation is the optimal RRT modality to prevent and correct growth failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link&amp;anchor=H118550707#H118550707\">",
"       \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\", section on 'Timing of RRT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link&amp;anchor=H363124528#H363124528\">",
"       \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\", section on 'Choice of RRT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children with renal allografts or those with nephrotic syndrome, glucocorticoid-sparing agents are used to minimize or avoid glucocorticoid therapy, a major contributor to poor growth. (See",
"      <a class=\"local\" href=\"#H359697803\">",
"       'Corticosteroid therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"       Recombinant human growth hormone",
"      </a>",
"      (rhGH) therapy to address",
"      <span class=\"nowrap\">",
"       GH/IGF-I",
"      </span>",
"      abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697775\">",
"    <span class=\"h1\">",
"     SUPPORTIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care should be provided to all children with chronic kidney disease (CKD) that include correcting and preventing any of the amenable contributing factors for growth impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359700278\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sufficient nutritional support including energy and protein intake is essential for normal growth, particularly for infants in whom growth is most sensitive to energy intake. Successful nutritional management requires a multidisciplinary team that includes physicians, skilled nurses, and dieticians.",
"   </p>",
"   <p>",
"    The energy intake should be 100 percent of the Dietary Reference Intake (DRI) based on age and gender (",
"    <a class=\"graphic graphic_table graphicRef56276 \" href=\"UTD.htm?27/59/28603\">",
"     table 2",
"    </a>",
"    ). Protein intake should be between 100 to 140 percent of DRI based on age and gender for children with CKD stage 3 and between 100 and 120 percent for those with CKD stages 4 and 5 (",
"    <a class=\"graphic graphic_table graphicRef81506 \" href=\"UTD.htm?21/52/22348\">",
"     table 3",
"    </a>",
"    ). In patients undergoing chronic peritoneal dialysis, protein intake should be increased to compensate for protein losses in the dialysate. A more detailed discussion on energy and protein intake requirements in children with CKD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enteral feeding is indicated in children with CKD when spontaneous calorie intake is insufficient to maintain growth. Routes for enteral findings include gastrostomy and nasogastric feedings. In an observational study of 153 young children (less than 24 months) who commenced peritoneal dialysis, gastrostomy feeding compared with either nasogastric feeding or demand feeding was associated with improved linear growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/3\">",
"     3",
"    </a>",
"    ]. This finding may be due to decreased episodes of vomiting associated with gastrostomies&nbsp;compared with nasogastric tubes.",
"   </p>",
"   <p>",
"    With early initiation of intensive nutritional and medical care including enteral feedings, severe growth failure in infants with CKD can be prevented with catch-up growth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a study from a single center of 101 infants with CKD, intensive nutrition (about 90 percent were fed enterally) and early renal transplantation resulted in a mean normal adult height in patients without comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, even optimal nutritional management may not be able to prevent growth failure in many patients, particularly older children with advanced stages of CKD. Analysis of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) database showed that catch-up growth without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) therapy was only observed in children aged younger than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/5\">",
"     5",
"    </a>",
"    ]. These results demonstrate that other factors such as disturbances of growth hormone metabolism and its primary mediator, insulin-like growth hormone-I",
"    <span class=\"nowrap\">",
"     (GH/IGF-I",
"    </span>",
"    axis), are important contributors to impaired growth in children with CKD, which optimal nutrition alone cannot overcome. As a result, rhGH therapy has been a beneficial intervention in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H113914234#H113914234\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Pathogenesis: Disturbance of GH/IGF-I axis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link&amp;anchor=H2#H2\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80286581\">",
"    <span class=\"h2\">",
"     Other supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other supportive measures include preventing or correcting the following risk factors that contribute to growth impairment in children with CKD (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=see_link&amp;anchor=H11319607#H11319607\">",
"     \"Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease\", section on 'Risk factors that contribute to impaired growth'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic acidosis &ndash; Prevention and correction of metabolic acidosis with administration of oral bicarbonate preparations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Metabolic acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolyte and fluid loss &ndash; Replacement of increased renal losses of fluids and electrolytes.",
"     </li>",
"     <li>",
"      Renal osteodystrophy &ndash; Monitoring mineral and bone status with routine measurements of serum calcium, phosphate, parathyroid hormone levels, and, if appropriate, 25-OH vitamin D levels. Interventions are initiated depending on laboratory results and include phosphate restriction, calcium and vitamin D supplementation, and the use of phosphate binders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link&amp;anchor=H10#H10\">",
"       \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia &ndash; Anemia is corrected with the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, apart from nutritional support in early infancy, true catch-up growth can rarely be obtained by any of these therapeutic interventions. At most, a growth pattern parallel to the growth percentiles is observed in response to optimization of nutritional support and medical treatment in children with CKD beyond infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11199014\">",
"    <span class=\"h1\">",
"     RENAL REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once children have reached end-stage renal disease (ie, chronic kidney disease [CKD] stage 5), growth rates generally continue to deteriorate. In particular, patients who receive chronic dialysis are at risk for growth failure. Even children who undergo renal transplantation and theoretically should have normal growth, and potentially catchup growth in prepubertal patients, still are at risk for growth impairment, particularly as a result of glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697782\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who undergo long-term conventional hemodialysis (ie, three treatments per week) generally have further deterioration of their growth (",
"    <a class=\"graphic graphic_figure graphicRef83843 \" href=\"UTD.htm?32/15/33022\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/6\">",
"     6",
"    </a>",
"    ]. This was illustrated by one case series of 51 children who underwent conventional hemodialysis for 12 to 111 months that reported a 0.4 standard deviation annual loss of mean relative height [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/7\">",
"     7",
"    </a>",
"    ]. In this study, one-third of the patients grew along the growth percentile attained at initiation of dialysis, one-third had slightly retarded growth, and one-third severely retarded growth.",
"   </p>",
"   <p>",
"    With increased intensity of nutrition and hemodialysis (eg, hemodiafiltration six times per week or nocturnal hemodialysis), single-center studies have reported that the growth rate of children on maintenance hemodialysis improved significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A possible mechanism behind this finding is that intensified dialysis improves clearance of solutes and middle molecules, and reverses the abnormalities of the growth",
"    <span class=\"nowrap\">",
"     hormone/insulin-like",
"    </span>",
"    growth factor-I",
"    <span class=\"nowrap\">",
"     (GH/IGF-I)",
"    </span>",
"    axis secondary to CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link&amp;anchor=H6760083#H6760083\">",
"     \"Hemodialysis for children with chronic kidney disease\", section on 'Length of dialysis and frequency of sessions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link&amp;anchor=H241185873#H241185873\">",
"     \"Hemodialysis for children with chronic kidney disease\", section on 'Growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697789\">",
"    <span class=\"h2\">",
"     Continuous peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth appears to be better after the start of continuous peritoneal dialysis in children, especially those below six years of age after conservative treatment or compared with hemodialysis (",
"    <a class=\"graphic graphic_figure graphicRef83844 \" href=\"UTD.htm?42/49/43806\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. This relative improvement in growth compared with hemodialysis has been partially attributed to the better nutritional status of patients as a consequence of their peritoneal glucose uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/11\">",
"     11",
"    </a>",
"    ]. Peritoneal dialysis is usually more effective in solute and fluid removal than conventional hemodialysis, and improved growth and nutritional status are correlated with increased solute and volume clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a gradual decline of relative height is frequently observed in children who have undergone long-term peritoneal dialysis, indicating that the impact of the dialysis modality on growth diminishes with time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These data temper the initial enthusiasm that peritoneal dialysis would result in a significant beneficial sustained impact on growth. At best, parallel growth along the child&rsquo;s growth percentile is achieved by peritoneal dialysis, but not persistent catch-up growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697796\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation is the optimal renal replacement therapy (RRT) modality to prevent and correct growth failure as a well-functioning allograft restores the physiological conditions required for normal growth. However, growth rates after renal transplantation in children are highly variable and often do not fulfill the expectations of true catch-up growth, which generally is only observed in children less than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/14\">",
"     14",
"    </a>",
"    ] . The main contributing factors to continued growth depression in pediatric renal allograft recipients are glucocorticoid treatment for immunosuppression and reduced graft function. The final height also depends on the age of the child and the severity of the growth failure at time of transplantation (",
"    <a class=\"graphic graphic_figure graphicRef83842 \" href=\"UTD.htm?16/55/17279\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link&amp;anchor=H118550707#H118550707\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\", section on 'Timing of RRT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link&amp;anchor=H363124528#H363124528\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\", section on 'Choice of RRT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link&amp;anchor=H13#H13\">",
"     \"Outcomes of renal transplantation in children\", section on 'Growth after renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697803\">",
"    <span class=\"h2\">",
"     Corticosteroid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily glucocorticoid therapy following renal transplantation or to treat glomerular disease is an important contributor to poor growth in children. Strategies to reduce the cumulative effects of glucocorticoid therapy include the use of alternate day glucocorticoids, late or early glucocorticoid withdrawal, and immunosuppressive regimens that avoid glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Efforts to reduce or eliminate glucocorticoid therapy for children with renal allografts are reviewed below. The use of glucocorticoid-sparing therapy in children with nephrotic syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Steroid side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H174702557#H174702557\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Choice of agent: Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697810\">",
"    <span class=\"h3\">",
"     Alternate day corticosteroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate day glucocorticoid regimen has a less inhibitory effect on growth velocity compared with daily administration and does not adversely affect graft survival or long-term graft function as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) registry of 2001 children with functioning allografts 12 months after transplantation, about 17 percent of patients (n = 337) were maintained on immunosuppressive therapy that included alternate day regimen of glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients who received alternate day glucocorticoids had a greater increase in relative height compared with those maintained on a daily glucocorticoid regimen (mean z height score difference of +0.5). There was no difference in graft survival or function between the two groups.",
"     </li>",
"     <li>",
"      In another study of 30 children below the age of five years at the time of kidney transplantation, maintenance immunosuppression consisted of cyclosporin A,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and alternate day glucocorticoid treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/17\">",
"       17",
"      </a>",
"      ]. Catch-up growth without",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      (rhGH) therapy was observed initially in 24 patients. However, in subsequent years (five to seven years after transplantation), only 10 children showed significant improved longitudinal growth. As noted above, catch-up growth is usually only observed in children less than five years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697817\">",
"    <span class=\"h3\">",
"     Corticosteroid withdrawal or avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of other immunosuppressive agents, particularly calcineurin inhibitors (ie, cyclosporin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) and the antimetabolite,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF), has permitted the reduction, and in some centers withdrawal or avoidance of glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Initial efforts were directed at withdrawing glucocorticoid therapy from maintenance immunosuppressive regimens as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a German trial of 42 children with low to moderate immunologic risk who were initially maintained on a combined immunosuppressive regimen of glucocorticoids, cyclosporin, and MMF, patients randomly assigned to glucocorticoid withdrawal after kidney transplantation had superior longitudinal growth compared with controls two years after withdrawal (mean z height score gain of +0.6 versus -0.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Patient and graft survival was 100 percent, and there were no differences in the risk of acute rejections and renal function between the two groups.",
"     </li>",
"     <li>",
"      In a trial in the United States of 132 pediatric renal allograft recipients who were treated with an immunosuppressive regimen of anti-CD25 antibody,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      , calcineurin inhibitor, and glucocorticoids, patients who were randomly assigned to glucocorticoid withdrawal had a greater height velocity than those who continued to receive low-dose glucocorticoid therapy 18 months post-transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/20\">",
"       20",
"      </a>",
"      ]. There were no differences in acute rejection episodes between the two groups. The three-year allograft survival rate was 84.5 percent in the control group and 98.6 percent in the glucocorticoid withdrawal group. However, the study was stopped early because of the high incidence of post-transplant lymphoproliferative disorder (PTLD, 6.9 percent) associated with this intense immunosuppressive therapy.",
"     </li>",
"     <li>",
"      In a long-term observational study of 74 pediatric patients followed for a mean of 8.5 years, glucocorticoids therapy was discontinued four to six months after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/21\">",
"       21",
"      </a>",
"      ]. In this cohort, adult height within the normal range, defined as a height z score &gt;-2 SD, was achieved in 94 percent of prepubertal (mean z score -0.5) and 80 percent of pubertal patients (mean z score of -1). Graft survival at 5 and 10 years was 92 and 71 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the success of discontinuing glucocorticoids as maintenance therapy in selected patients, subsequent research has been directed toward restricting glucocorticoid therapy for use only during induction immunosuppression (not included in maintenance immunosuppression) as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial, patients randomly assigned to a regimen of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , MMF, and early glucocorticoid withdrawal (at day five) following two doses of daclizumab (anti-interleukin 2 [IL2] receptor antibody) had a greater height gain compared with patients who received triple therapy with tacrolimus, MMF, and continued glucocorticoid therapy six months after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/22\">",
"       22",
"      </a>",
"      ]. There were no differences in allograft survival and risk of acute rejection at six-month follow-up. However, daclizumab is no longer available due to reduced market demands. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link&amp;anchor=H35218129#H35218129\">",
"       \"Immunosuppression in renal transplantation in children\", section on 'Anti-interleukin 2 receptor antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a second non-randomized comparative trial that utilizes",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/58/28582?source=see_link\">",
"       basiliximab",
"      </a>",
"      , another anti-IL2 receptor antibody, patients randomly assigned to basiliximab,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , MMF, and early glucocorticoid withdrawal had better growth five years after transplantation than the matched control group who received tacrolimus, MMF, and glucocorticoids, (mean z score gains of +1.4 versus +1.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/23\">",
"       23",
"      </a>",
"      ]. There were no differences in allograft survival and function, and risk of acute rejections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An even more promising approach than early glucocorticoid withdrawal would be the complete avoidance of glucocorticoids. This may only be feasible in patients with low or moderate immunologic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/24\">",
"     24",
"    </a>",
"    ]. Data are limited and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 129 consecutive pediatric renal allograft recipients, outcome of patients who received a glucocorticoid-free regimen consisting of extended (up to six doses for six months posttransplant) daclizumab induction,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and MMF was compared with historical controls [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/25\">",
"       25",
"      </a>",
"      ]. Of note,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/14/10472?source=see_link\">",
"       sirolimus",
"      </a>",
"      was given to patients who did not tolerate MMF. Linear growth was better in patients who were treated with the glucocorticoid-free regimen, and the effect was greatest in patients younger than five years of age. In these patients, catch-up growth rates were higher than those in normal, healthy, age- and gender-matched controls. Graft function two years post-transplant was better in the glucocorticoid-free group compared with historical controls, and the rates of rejection were low in both groups. There was one case of PTLD.",
"     </li>",
"     <li>",
"      Similar results have been observed in smaller case series from other centers that have also utilized a regimen of daclizumab,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17240/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these encouraging results, there remains significant uncertainty regarding the most effective and safe immunosuppressive regimen that eliminates glucocorticoid therapy in pediatric renal allograft recipients, especially those with high immunologic risk.",
"   </p>",
"   <p>",
"    Immunosuppressive regimens for children undergoing renal transplantation that avoid or discontinue glucocorticoid therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link&amp;anchor=H533861718#H533861718\">",
"     \"Immunosuppression in renal transplantation in children\", section on 'Corticosteroid withdrawal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link&amp;anchor=H35218229#H35218229\">",
"     \"Immunosuppression in renal transplantation in children\", section on 'Immunosuppression combinations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link&amp;anchor=H784212492#H784212492\">",
"     \"Immunosuppression in renal transplantation in children\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12337646\">",
"    <span class=\"h1\">",
"     RECOMBINANT HUMAN GROWTH HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    (rhGH) therapy is safe and effective in improving growth in children with chronic kidney disease (CKD) including allograft recipients. The benefits, indications, dosing, and side effects of rhGH are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359697838\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth retardation is a major complication of children with chronic kidney disease (CKD).",
"   </p>",
"   <p>",
"    The management approach to prevent and correct growth impairment combines supportive measures that focus on amenable complications of CKD, renal replacement therapy, particularly renal transplantation, reduction and avoidance of glucocorticoid therapy, and the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that supportive care be provided to all children with CKD that corrects and prevents amenable contributing factors for growth impairment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This includes early initiation of optimal nutrition for all children with CKD, which may require enteral feeding (eg, gastrostomy and nasogastric feeding) to ensure both adequate energy and protein intake (",
"      <a class=\"graphic graphic_table graphicRef56276 \" href=\"UTD.htm?27/59/28603\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81506 \" href=\"UTD.htm?21/52/22348\">",
"       table 3",
"      </a>",
"      ). Other risk factors and their interventions include metabolic acidosis (bicarbonate therapy), electrolyte and fluid abnormalities (replacement of excessive renal losses), renal osteodystrophy (vitamin D and calcium supplementation and phosphate restriction), and anemia (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H359697775\">",
"       'Supportive measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once children have reached end-stage renal disease (ESRD, CKD stage 5), growth rates generally deteriorate. In children with ESRD, we recommend renal transplantation as the preferred renal replacement therapy that promotes growth and overall quality of life (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If transplantation is not an option, modest initial gains in relative height can be achieved with intensive nutritional intervention in children who are treated with peritoneal dialysis or intensive hemodialysis. (See",
"      <a class=\"local\" href=\"#H11199014\">",
"       'Renal replacement therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link\">",
"       \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although renal transplantation is the preferred renal replacement therapy (RRT), growth may be impaired, especially in children who receive daily glucocorticoid treatment for immunosuppression or have an allograft with reduced function. In addition, the final height is dependent on age of the child and the severity of the growth failure at time of transplantation. (See",
"      <a class=\"local\" href=\"#H359697796\">",
"       'Transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link&amp;anchor=H13#H13\">",
"       \"Outcomes of renal transplantation in children\", section on 'Growth after renal transplantation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The introduction of new therapeutic agents has permitted the use of immunosuppressive regimens that reduce or eliminate glucocorticoid therapy, which has improved growth in pediatric renal allograft recipients. Ongoing studies are focused on determining the optimal regimen for long-term patient and graft survival, improved growth and quality of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link&amp;anchor=H533861718#H533861718\">",
"       \"Immunosuppression in renal transplantation in children\", section on 'Corticosteroid withdrawal'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link&amp;anchor=H784212492#H784212492\">",
"       \"Immunosuppression in renal transplantation in children\", section on 'Our approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"       Recombinant human growth hormone",
"      </a>",
"      (rhGH) is a safe therapeutic intervention that promotes growth in children with CKD including those who are pediatric renal allograft recipients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"       \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/1\">",
"      Mahan JD, Warady BA, Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006; 21:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/2\">",
"      Andr&eacute; JL, Bourquard R, Guillemin F, et al. Final height in children with chronic renal failure who have not received growth hormone. Pediatr Nephrol 2003; 18:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/3\">",
"      Rees L, Azocar M, Borzych D, et al. Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol 2011; 22:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/4\">",
"      Mekahli D, Shaw V, Ledermann SE, Rees L. Long-term outcome of infants with severe chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/5\">",
"      Seikaly MG, Salhab N, Gipson D, et al. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol 2006; 21:793.",
"     </a>",
"    </li>",
"    <li>",
"     North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual dialysis report. https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/7\">",
"      Kleinknecht C, Broyer M, Gagnadoux MF, et al. Growth in children treated with long-term dialysis. A study of 76 patients. Adv Nephrol Necker Hosp 1980; 9:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/8\">",
"      Fischbach M, Terzic J, Menouer S, et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant 2010; 25:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/9\">",
"      Hoppe A, von Puttkamer C, Linke U, et al. A hospital-based intermittent nocturnal hemodialysis program for children and adolescents. J Pediatr 2011; 158:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/10\">",
"      Stefanidis CJ, Hewitt IK, Balfe JW. Growth in children receiving continuous ambulatory peritoneal dialysis. J Pediatr 1983; 102:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/11\">",
"      Schaefer F, Klaus G, Mehls O. Peritoneal transport properties and dialysis dose affect growth and nutritional status in children on chronic peritoneal dialysis. Mid-European Pediatric Peritoneal Dialysis Study Group. J Am Soc Nephrol 1999; 10:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/12\">",
"      Fine RN, Salusky IB. CAPD/CCPD in children: four years' experience. Kidney Int Suppl 1986; 19:S7.",
"     </a>",
"    </li>",
"    <li>",
"     International Pediatric Peritoneal Dialysis Network. About IPPN [online] file://www.pedpd.org/index.php?id=98 (Accessed on May 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/14\">",
"      Tejani A, Fine R, Alexander S, et al. Factors predictive of sustained growth in children after renal transplantation. The North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1993; 122:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/15\">",
"      Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 1992; 120:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/16\">",
"      Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996; 61:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/17\">",
"      Qvist E, Marttinen E, R&ouml;nnholm K, et al. Growth after renal transplantation in infancy or early childhood. Pediatr Nephrol 2002; 17:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/18\">",
"      H&ouml;cker B, Weber LT, Feneberg R, et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009; 87:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/19\">",
"      H&ouml;cker B, Weber LT, Feneberg R, et al. Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrol Dial Transplant 2010; 25:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/20\">",
"      Benfield MR, Bartosh S, Ikle D, et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010; 10:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/21\">",
"      Klare B, Montoya CR, Fischer DC, et al. Normal adult height after steroid-withdrawal within 6 months of pediatric kidney transplantation: a 20 years single center experience. Transpl Int 2012; 25:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/22\">",
"      Grenda R, Watson A, Trompeter R, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 2010; 10:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/23\">",
"      Delucchi A, Valenzuela M, Lillo AM, et al. Early steroid withdrawal in pediatric renal transplant: five years of follow-up. Pediatr Nephrol 2011; 26:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/24\">",
"      Grenda R, Webb NJ. Steroid minimization in pediatric renal transplantation: Early withdrawal or avoidance? Pediatr Transplant 2010; 14:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/25\">",
"      Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/26\">",
"      Silverstein DM, Aviles DH, LeBlanc PM, et al. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients. Pediatr Transplant 2005; 9:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17240/abstract/27\">",
"      Bhakta N, Marik J, Malekzadeh M, et al. Can pediatric steroid-free renal transplantation improve growth and metabolic complications? Pediatr Transplant 2008; 12:854.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83284 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17240=[""].join("\n");
var outline_f16_53_17240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H359697838\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359700116\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359700212\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359700220\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359700228\">",
"      Growth measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359697767\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359697775\">",
"      SUPPORTIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359700278\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80286581\">",
"      Other supportive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11199014\">",
"      RENAL REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359697782\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359697789\">",
"      Continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359697796\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359697803\">",
"      Corticosteroid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H359697810\">",
"      - Alternate day corticosteroid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H359697817\">",
"      - Corticosteroid withdrawal or avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12337646\">",
"      RECOMBINANT HUMAN GROWTH HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359697838\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/83284\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83284|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/15/33022\" title=\"figure 1\">",
"      Height velocity in children on hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/49/43806\" title=\"figure 2\">",
"      Height velocity in children on peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/55/17279\" title=\"figure 3\">",
"      Standarized height score by age at transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83284|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22603\" title=\"table 1\">",
"      Stages of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/59/28603\" title=\"table 2\">",
"      Energy intake CKD children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/52/22348\" title=\"table 3\">",
"      Protein intake CKD children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=related_link\">",
"      Hemodialysis for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=related_link\">",
"      Immunosuppression in renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=related_link\">",
"      Outcomes of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=related_link\">",
"      Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36713?source=related_link\">",
"      Pathogenesis, evaluation and diagnosis of growth impairment in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17241="Approach to hypertensive emergencies and urgencies in children";
var content_f16_53_17241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to hypertensive emergencies and urgencies in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17241/contributors\">",
"     Jordan Symons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17241/contributors\">",
"     Brianna Enriquez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17241/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17241/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17241/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17241/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/53/17241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive emergencies occur rarely in children. Proper management of this life-threatening disorder depends on prompt recognition and treatment. Inadequate awareness of pediatric blood pressure (BP) norms, poor technique resulting in inaccurate measurements, or failure to obtain blood pressure measurements in the pediatric ambulatory setting prevents recognition of this clinical condition.",
"   </p>",
"   <p>",
"    This topic addresses the diagnostic approach to hypertensive emergencies in children. The treatment of pediatric hypertensive emergencies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, defined as either systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic BP &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile measured upon three or more occasions, is present in 3 to 5 percent of the pediatric population and is frequently undiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, hypertensive emergencies in children occur in fewer than 1 percent of ED visits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper management of children with elevated BP requires working knowledge of pediatric BP standards and a clear understanding of when elevated BP requires emergent, urgent, or routine care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypertension in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is defined as either systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic BP &ge;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile measured upon three or more occasions. The degree of hypertension is further delineated by the two following stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 hypertension &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile and 5 mmHg above the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile.",
"     </li>",
"     <li>",
"      Stage 2 hypertension &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision process for evaluation and treatment varies with the severity of the hypertension. Stage 2 identifies those children who need more prompt evaluation and immediate pharmacologic treatment, while stage 1 hypertension allows for more time for evaluation and initial treatment with nonpharmacologic therapy unless the patient is symptomatic or has hypertensive target-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition of childhood hypertension is statistically defined based upon the normative distribution of BP obtained in tens of thousands of children at pediatric office visits and is adjusted for gender, age, and height (",
"    <a class=\"graphic graphic_figure graphicRef62371 graphicRef75178 \" href=\"UTD.htm?3/49/3859\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"     table 2",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recognition of hypertension in neonates and infants also depends on comparison with standards. However, these BP measurements are adjusted for differing parameters than in children over one year of age: birth weight and postconceptual age for neonates (",
"    <a class=\"graphic graphic_table graphicRef76354 \" href=\"UTD.htm?15/56/16270\">",
"     table 3",
"    </a>",
"    ); age and to a limited extent weight and length for the perinatal period up to one year of age (",
"    <a class=\"graphic graphic_figure graphicRef62371 graphicRef75178 \" href=\"UTD.htm?3/49/3859\">",
"     figure 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44630?source=see_link&amp;anchor=H21347114#H21347114\">",
"     \"Hypertension in infants between one month and one year of age\", section on 'Normal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link&amp;anchor=H2915543#H2915543\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\", section on 'Normal BP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertensive emergency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe symptomatic elevation in BP WITH evidence of acute target organ damage defines a hypertensive emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The most commonly involved organs are the brain (seizures, increased intracranial pressure), kidneys (renal insufficiency), eyes (papilledema, retinal hemorrhages, exudates), and heart (heart failure).",
"   </p>",
"   <p>",
"    The absolute degree of BP elevation is less important than whether end organ symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    damage is present and is associated with an acute change in mean arterial pressure. For example, a child with chronic hypertension may have very high BP measurements with no symptoms. Another child with an acute rise in BP may manifest a hypertensive emergency despite a BP that is only moderately elevated. Careful intervention to lower blood pressure should begin emergently upon recognition of a hypertensive emergency, and should be accomplished with intravenous antihypertensive agents (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hypertensive encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive emergencies in children usually manifest as hypertensive encephalopathy: severe BP elevation with cerebral edema and neurological symptoms of lethargy, coma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures. This pathology is caused by cerebrovascular endothelium breakdown secondary to failure of cerebral autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H1#H1\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Malignant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;This term describes marked hypertension with retinal hemorrhages, exudates, or papilledema. There may also be renal involvement, called malignant nephrosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H1#H1\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypertensive urgency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe elevation in BP WITHOUT severe symptoms or evidence of acute target organ damage describes a hypertensive urgency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. A child with hypertensive urgency warrants an immediate evaluation. When the urgency arises from an acute process with a rapid change in mean arterial pressure, intervention should occur promptly and treatment with intravenous antihypertensive medications is appropriate (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 4",
"    </a>",
"    ). However, in the setting of a chronic condition (eg, chronic pyelonephritis), where blood pressure has increased gradually over time, lowering of the blood pressure should occur less quickly (eg, hours to days) (",
"    <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"     algorithm 1",
"    </a>",
"    ). Management of hypertensive urgencies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current evidence concerning the pathogenesis of hypertensive emergencies is primarily derived from animal and adult studies and highlights the effect of elevated BP, renin release, oxidative stress, and endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure elevation &ndash; Autoregulation of BP maintains stable perfusion of end organs within a range of mild to moderately elevated BP. Once the BP exceeds the autoregulatory zone, excess pressure is applied to the distal vasculature resulting in increased vessel permeability, endothelial damage, and arteriolar fibrinoid necrosis. These effects combine to cause tissue edema, vasoconstriction, and tissue ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary or secondary renin release &ndash; Renin release from the juxtaglomerular apparatus of the kidney leads to increased levels of angiotensin I that is subsequently converted into angiotensin II in the lungs. Angiotensin II promotes vasoconstriction, NADPH oxidase activity, and expression of proinflammatory cytokines. Increased NADPH oxidase activity produces reactive oxygen species. Release of proinflammatory cytokines causes local inflammation, proliferation of vascular smooth muscle cells, and endothelial damage. The end result is progressive cytotoxic effects and tissue ischemia occurring in a self-perpetuating cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oxidative stress &ndash; Oxidative stress reduces nitric oxide levels, thereby inhibiting vasodilation. Reactive oxygen species (eg, chemical agents with oxygen free radicals) may also directly damage blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endothelial dysfunction &ndash; BP elevation, renin release, and oxidative stress together cause endothelial dysfunction. The hallmarks of endothelial dysfunction are vasoconstriction, perivascular inflammation and activation of the coagulation cascade. These events result in vascular obstruction, target organ damage, and severe elevation in BP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination should first focus on signs of acute organ symptom",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    damage and then seek to identify the underlying etiology once treatment has been initiated (",
"    <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/4,15-19\">",
"     4,15-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Symptoms of end organ damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of change in behavior, altered mental status, vision changes, heart failure, or kidney disease are key components of an initial history in the child with significant hypertension (",
"    <a class=\"graphic graphic_table graphicRef76420 \" href=\"UTD.htm?30/40/31372\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system causes must be considered early, as a surgical lesion may be present. Visual changes, headache (especially awakening from sleep or associated with morning vomiting), seizures, confusion, focal weakness, or other neurological symptoms suggest increased intracranial pressure.",
"     </li>",
"     <li>",
"      History of recent head injury markedly changes the treatment plan since hypertension secondary to primary intracranial injury requires treatment that maintains cerebral perfusion pressure as the primary therapeutic goal and should not be managed with antihypertensive medication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"       \"Initial approach to severe traumatic brain injury in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to hypertensive encephalopathy, visual changes may also result from retinal hemorrhage or exudates that involve the macula (central vision) or cause noticeable defects in peripheral vision.",
"     </li>",
"     <li>",
"      Shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, and edema indicate heart failure (HF). In the infant, diaphoresis or tachypnea with feeding is an additional finding that suggests HF as a primary etiology.",
"     </li>",
"     <li>",
"      Flank pain, dysuria, hematuria, frothy \"tea-colored\" urine, and",
"      <span class=\"nowrap\">",
"       oliguria/anuria",
"      </span>",
"      are common manifestations of acute kidney injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following organs are frequently affected in hypertensive emergencies: eye, brain, heart, adrenal gland, thyroid gland, and kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/8,9,12-14\">",
"     8,9,12-14",
"    </a>",
"    ]. Thus, findings referable to these structures deserve special emphasis in the history (",
"    <a class=\"graphic graphic_table graphicRef76420 \" href=\"UTD.htm?30/40/31372\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Children with existing secondary hypertension are at highest risk for the development of a hypertensive emergency, especially those patients without prior knowledge of underlying hypertension and those not adherent to therapy. Thus, a history of known hypertension, chronic kidney disease, or genitourinary abnormality in the patient is of particular importance.",
"   </p>",
"   <p>",
"    In addition, the following factors identify children and adolescents at risk for hypertensive emergencies (",
"    <a class=\"graphic graphic_table graphicRef76420 \" href=\"UTD.htm?30/40/31372\">",
"     table 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria, edema, or diminished urinary output, suggestive of glomerulonephritis or other parenchymal renal disease.",
"     </li>",
"     <li>",
"      History of umbilical artery or vein catheterization which predisposes to renovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"       \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preceding streptococcal infection involving the skin or pharynx indicating poststreptococcal glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41193?source=see_link&amp;anchor=H31#H31\">",
"       \"Group A streptococcus: Virulence factors and pathogenic mechanisms\", section on 'Poststreptococcal glomerulonephritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy, especially adolescents or nulliparous females who are at highest risk for preeclampsia or eclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H3#H3\">",
"       \"Preeclampsia: Clinical features and diagnosis\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recreational, prescription, and over-the-counter drug use associated with hypertension in overdose, especially cocaine, amphetamines, anabolic steroids, PCP,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      , ephedra-containing alternative medications, oral contraceptives, and corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link&amp;anchor=H11#H11\">",
"       \"Cocaine: Acute intoxication\", section on 'Cardiovascular complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=see_link&amp;anchor=H8#H8\">",
"       \"Phencyclidine (PCP) intoxication in children and adolescents\", section on 'Clinical features of overdose'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link&amp;anchor=H4#H4\">",
"       \"MDMA (ecstasy) intoxication\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link&amp;anchor=H4#H4\">",
"       \"Methamphetamine intoxication\", section on 'Clinical features of overdose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recent use of serotonergic agents or inadvertent coadministration of serotonergic medications causing serotonin syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight loss, anxiety, and heat intolerance suggesting hyperthyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of catecholamine excess such as tachycardia, pallor, headaches, and diaphoresis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=see_link\">",
"       \"Pheochromocytoma in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial assessment of the child with a hypertensive emergency should focus on airway, breathing, and circulation (",
"    <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"     table 5",
"    </a>",
"    ). In addition to vital signs (including pulse oximetry), four-extremity BP should be obtained, as a patient with coarctation of the aorta may exhibit lower BP in the legs than in the right upper extremity. Right arm BP may also exceed left arm BP if the aortic coarctation occurs proximal to the origin of the left subclavian artery. Additional physical findings help identify the severity of the hypertensive emergency and the likely etiology (",
"    <a class=\"graphic graphic_table graphicRef79975 \" href=\"UTD.htm?33/61/34781\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Blood pressure measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate BP measurement requires use of the proper cuff size. Recommendations cite BP by auscultation as the best technique [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/4,15,18\">",
"     4,15,18",
"    </a>",
"    ]. The cuff size should have a bladder width that is approximately 40 percent of the circumference of the upper arm, measured midway between the olecranon and the acromion (",
"    <a class=\"graphic graphic_figure graphicRef73414 \" href=\"UTD.htm?1/0/1025\">",
"     figure 2",
"    </a>",
"    ). The length of the cuff bladder should encircle 80 to 100 percent of the circumference of the upper arm midway between the olecranon and the acromion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/15,20,21\">",
"     15,20,21",
"    </a>",
"    ]. The bladder width-to-length should be at least 1:2 (",
"    <a class=\"graphic graphic_figure graphicRef73414 \" href=\"UTD.htm?1/0/1025\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58304 \" href=\"UTD.htm?36/49/37659\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Technique of BP measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oscillometric BP measurement is acceptable, although elevated BP values greater than the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile obtained by oscillometric methods require confirmation by auscultation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/15,19\">",
"       15,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intra-arterial BP measurement remains the most accurate technique for monitoring BP and provides continuous readings that best guide therapy in hypertensive emergencies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"       \"Management of hypertensive emergencies and urgencies in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Signs of end organ damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive encephalopathy is the most common type of hypertensive emergency in children. Altered mental status or seizures occurred in 50 percent of 110 patients in one retrospective series. Other clinical findings of end organ damage in these patients included hypertensive retinopathy (27 percent) and left ventricular hypertrophy (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system (CNS) &ndash; CNS findings include altered mental status (lethargy, coma, confusion), seizures, and irritability (infants). Facial nerve palsy, vision change, and hemiplegia are other reported CNS findings in children with hypertensive emergencies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to initiating treatment for a hypertensive emergency, it is imperative to exclude head trauma or mass lesion as the underlying cause of neurologic symptoms. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Other signs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye &ndash; Funduscopic examination is of particular importance since papilledema and retinal hemorrhage or exudates may be the only sign of a hypertensive emergency (",
"      <a class=\"graphic graphic_picture graphicRef78225 graphicRef57183 \" href=\"UTD.htm?30/56/31620\">",
"       picture 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"       \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=see_link\">",
"       \"Ocular effects of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart &ndash; Heart failure secondary to a hypertensive emergency may have findings of left ventricular heart failure (tachypnea, pulmonary edema, S3 or S4 gallop rhythm, and new or changed heart murmur). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal &ndash; Hematuria and proteinuria may represent manifestations of glomerulonephritis, a common cause of hypertensive emergency. Rarely, acute hypertension can result in acute kidney injury with hematuria, proteinuria, or flank pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should carefully examine the patient for clues to the underlying etiology for the hypertensive emergency as well as evidence for alternative reasons for elevated blood pressure (",
"    <a class=\"graphic graphic_table graphicRef79975 \" href=\"UTD.htm?33/61/34781\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76824 \" href=\"UTD.htm?31/61/32733\">",
"     table 9",
"    </a>",
"    ). Key areas of focus include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral edema, suggesting fluid overload in association with renal disease or renal failure.",
"     </li>",
"     <li>",
"      Exophthalmos and thyromegaly associated with hyperthyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diminished femoral pulses relative to brachial pulses indicating coarctation of the aorta. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal mass suggesting Wilms tumor, neuroblastoma, polycystic kidney disease or other congenital renal anomaly.",
"     </li>",
"     <li>",
"      Abdominal or flank bruit arising from renovascular disease.",
"     </li>",
"     <li>",
"      Skin findings suggesting neurofibromatosis (eg, cafe au lait spots, axillary freckling, cutaneous neurofibromas) or tuberous sclerosis (eg, Shagreen [ash leaf] patches, angiofibromas of the malar region of the face, ungual fibromas). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link&amp;anchor=H5#H5\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs of head trauma (contusion, laceration, hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 2",
"      </a>",
"      ), palpable skull defect).",
"     </li>",
"     <li>",
"      Signs of sympathomimetic overdose (toxidrome) (",
"      <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"       table 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Evidence of child abuse (bruises in varying stages of healing, loop marks, retinal hemorrhage, and fractures). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"       \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with a hypertensive emergency warrant the following studies (",
"    <a class=\"graphic graphic_table graphicRef57292 \" href=\"UTD.htm?11/26/11691\">",
"     table 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of hypertension in children and adolescents\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of BUN, serum creatinine, electrolytes, and glucose along with microscopic urinalysis. These tests quickly assess renal function and indicate the presence of renal parenchymal disease.",
"     </li>",
"     <li>",
"      Complete blood count and reticulocyte count to assess for possible anemia or thrombocytopenia often associated with rheumatic disorders with significant renal involvement (eg, systemic lupus erythematosus).",
"     </li>",
"     <li>",
"      Chest radiograph and electrocardiogram to screen for cardiac hypertrophy and heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are dictated by the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine toxicological screen testing for amphetamines, phencyclidine, and metabolites of cocaine in patients with a sympathomimetic toxidrome.",
"     </li>",
"     <li>",
"      Urine pregnancy test in all postmenarchal females to screen for preeclampsia.",
"     </li>",
"     <li>",
"      Computed tomography of the brain in patients with hypertensive encephalopathy to evaluate for cerebral edema, intracranial hemorrhage, and stroke and to differentiate hypertensive encephalopathy from intracranial injury or mass lesion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"       \"Initial approach to severe traumatic brain injury in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=see_link\">",
"       \"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When indicated, echocardiography provides more specific information regarding left ventricular mass and function than does EKG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other specialized renal diagnostic studies may be delayed pending successful treatment of the hypertensive emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of hypertension in children and adolescents\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF HYPERTENSIVE EMERGENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to adults, where uncontrolled essential hypertension is the overwhelming cause of a hypertensive emergency, children are more likely to have secondary hypertension. The etiology of hypertensive emergencies varies significantly by age and largely parallels underlying causes of hypertension (",
"    <a class=\"graphic graphic_table graphicRef73225 \" href=\"UTD.htm?37/15/38139\">",
"     table 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69333 \" href=\"UTD.htm?0/6/104\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=see_link\">",
"     \"Evaluation of hypertension in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link\">",
"     \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young infants with hypertensive emergencies typically have renovascular disease or congenital renal anomalies. The majority of neonatal renovascular disease is caused by umbilical arterial catheterization with subsequent thromboembolism of either the aorta or renal arteries. Other age-specific causes include coarctation of the aorta, renal vein thrombosis, renal parenchymal disease, bronchopulmonary dysplasia, congenital adrenal hyperplasia, and iatrogenic fluid overload [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/16,25,26\">",
"     16,25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children outside of the neonatal period commonly have glomerulonephritis, renovascular disease, or endocrine disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology, risk factors, and etiology of hypertension in children and adolescents\", section on 'Secondary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although renal parenchymal disease is also frequent, preeclampsia, sympathomimetic drug intoxication (eg, cocaine, amphetamine exposure), and serotonin syndrome are important secondary causes of severe hypertension in teenagers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a patient presenting to the emergency department with severe hypertension requires immediate confirmation of marked BP elevation, rapid assessment of severity of disease, exclusion of other causes of severe hypertension for which rapid reduction of BP might be harmful (eg, intracranial injury or mass lesion), and emergent antihypertensive therapy (",
"    <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Confirm elevated BP",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a severely elevated BP is obtained, the clinician should reassess the BP using auscultation (",
"    <a class=\"graphic graphic_figure graphicRef73414 \" href=\"UTD.htm?1/0/1025\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58304 \" href=\"UTD.htm?36/49/37659\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Technique of BP measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated BP values greater than the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile obtained by oscillometric methods require confirmation by auscultation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17241/abstract/15,19\">",
"       15,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intra-arterial BP measurement remains the most accurate technique for monitoring BP and provides continuous readings that best guide therapy in hypertensive emergencies. However, in the setting of a hypertensive emergency, treatment should not be delayed by arterial cannulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Establish severity of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the blood pressure remains elevated, a focused history and physical examination should be performed to identify evidence of end organ damage. At minimum, a complete neurologic, cardiac, and funduscopic exam must be performed and findings of renal pathology such as edema, palpable kidneys, and an abdominal bruit should be sought. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Symptoms of end organ damage'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Signs of end organ damage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Exclude other causes of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to antihypertensive therapy, it is imperative to ensure that elevated BP is not caused by severe pain, increased intracranial pressure (ICP) secondary to intracranial injury or mass, coarctation of the aorta, or ingestion of sympathomimetic agents (eg, cocaine, amphetamines, phencyclidine), because lowering of BP may be contraindicated (elevated ICP, coarctation of the aorta) or accomplished by different means (eg, benzodiazepine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"     phentolamine",
"    </a>",
"    administration with cocaine overdose or analgesia for severe pain). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link\">",
"     \"Management of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treat hypertensive emergency",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the physical examination, laboratory studies, or ancillary studies demonstrate that the patient has evidence of end organ damage, they are classified as having a hypertensive emergency and emergent reduction in the blood pressure with intravenous medication must be pursued (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 4",
"    </a>",
"    ). The choice of medication should be dictated by the suspected underlying cause of the hypertensive emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of hypertensive emergencies and urgencies in children\", section on 'Approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of hypertensive emergencies and urgencies in children\", section on 'Specific pediatric hypertensive emergencies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=see_link&amp;anchor=H155183150#H155183150\">",
"     \"Management of hypertension in infants\", section on 'Severe symptomatic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no published large clinical trials evaluating management of hypertensive emergencies in children. The goal of treatment in pediatric patients with acute hypertension and life-threatening symptoms (eg, seizures)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    target-organ involvement is to lower the blood pressure promptly by no more than 25 percent within the first eight hours of treatment.",
"   </p>",
"   <p>",
"    Rapid lowering of BP to less than 25 percent of maximum BP may lead to permanent end organ damage due to hypertension-induced abnormalities of autoregulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of hypertensive emergencies and urgencies in children\", section on 'Approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of hypertensive emergencies and urgencies in children\", section on 'Specific pediatric hypertensive emergencies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=see_link&amp;anchor=H155183150#H155183150\">",
"     \"Management of hypertension in infants\", section on 'Severe symptomatic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After initiation of treatment in the emergency department, the patient should be admitted to the intensive care unit for continued management with input from a nephrologist or other physician with pediatric expertise in managing hypertension in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview establishes key steps in the approach to the child with severe hypertension (",
"    <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"     table 5",
"    </a>",
"    ). Treatment of hypertensive emergencies in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link\">",
"     \"Management of hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definition of childhood hypertension is statistically defined based upon the normative distribution of BP obtained in tens of thousands of children at pediatric office visits and is adjusted for gender, age, and height (",
"      <a class=\"graphic graphic_figure graphicRef62371 graphicRef75178 \" href=\"UTD.htm?3/49/3859\">",
"       figure 1A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"       table 2",
"      </a>",
"      )(",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recognition of hypertension in neonates and infants also depends on comparison with standards. However, these BP measurements are adjusted for differing parameters than in children over one year of age: birth weight and postconceptual age for neonates (",
"      <a class=\"graphic graphic_table graphicRef76354 \" href=\"UTD.htm?15/56/16270\">",
"       table 3",
"      </a>",
"      ); age and to a limited extent weight and length for the perinatal period up to one year of age (",
"      <a class=\"graphic graphic_figure graphicRef62371 graphicRef75178 \" href=\"UTD.htm?3/49/3859\">",
"       figure 1A-B",
"      </a>",
"      )&nbsp;. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44630?source=see_link&amp;anchor=H21347114#H21347114\">",
"       \"Hypertension in infants between one month and one year of age\", section on 'Normal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link&amp;anchor=H2915543#H2915543\">",
"       \"Etiology, clinical features, and diagnosis of neonatal hypertension\", section on 'Normal BP'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A severe symptomatic elevation in BP WITH evidence of acute target organ damage defines a hypertensive emergency. Careful intervention to lower blood pressure should begin emergently upon recognition of a hypertensive emergency, and should be accomplished with intravenous antihypertensive agents (",
"      <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treat hypertensive emergency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H27#H27\">",
"       \"Management of hypertensive emergencies and urgencies in children\", section on 'Management of hypertensive emergency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A severe elevation in BP WITHOUT severe symptoms or evidence of acute target organ damage describes a hypertensive urgency. A child with hypertensive urgency warrants an immediate evaluation. Management depends on whether BP elevation is acute or chronic. (",
"      <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypertensive urgency'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=see_link&amp;anchor=H28#H28\">",
"       \"Management of hypertensive emergencies and urgencies in children\", section on 'Management of hypertensive urgency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Evaluation for hypertensive emergency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accurate BP measurement requires use of the proper cuff size. Recommendations cite BP by auscultation as the best technique. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H13#H13\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Technique of BP measurement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The history and physical examination should first focus on findings of acute organ damage and then seek to identify the underlying etiology once treatment has been initiated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial ancillary studies help establish evidence of renal or cardiac damage and in selected patients, identify specific etiologies for the hypertensive emergency, such as poststreptococcal glomerulonephritis, preeclampsia or eclampsia, or sympathomimetic overdose (",
"      <a class=\"graphic graphic_table graphicRef57292 \" href=\"UTD.htm?11/26/11691\">",
"       table 11",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to adults, where uncontrolled essential hypertension is the overwhelming cause of a hypertensive emergency, children are more likely to have secondary hypertension. The etiology of hypertensive emergencies varies significantly by age and largely parallels underlying causes of hypertension (",
"      <a class=\"graphic graphic_table graphicRef73225 \" href=\"UTD.htm?37/15/38139\">",
"       table 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69333 \" href=\"UTD.htm?0/6/104\">",
"       table 13",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Etiology of hypertensive emergency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/1\">",
"      Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/2\">",
"      Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007; 298:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/3\">",
"      Moore WE, Stephens A, Wilson T, et al. Body mass index and blood pressure screening in a rural public school system: the Healthy Kids Project. Prev Chronic Dis 2006; 3:A114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/4\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/5\">",
"      Flanigan JS, Vitberg D. Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat. Med Clin North Am 2006; 90:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/6\">",
"      Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/7\">",
"      Constantine E, Linakis J. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care 2005; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/8\">",
"      Fenves AZ, Ram CV. Drug treatment of hypertensive urgencies and emergencies. Semin Nephrol 2005; 25:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/9\">",
"      Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care 2003; 7:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/10\">",
"      Adelman RD, Coppo R, Dillon MJ. The emergency management of severe hypertension. Pediatr Nephrol 2000; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/11\">",
"      Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/12\">",
"      Patel HP, Mitsnefes M. Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 2005; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/13\">",
"      Lass&egrave;gue B, Griendling KK. Reactive oxygen species in hypertension; An update. Am J Hypertens 2004; 17:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/14\">",
"      Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/15\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/16\">",
"      Flynn JT. Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000; 14:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/17\">",
"      Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/18\">",
"      G&oacute;mez-Mar&iacute;n O, Prineas RJ, R&aring;stam L. Cuff bladder width and blood pressure measurement in children and adolescents. J Hypertens 1992; 10:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/19\">",
"      Park MK, Menard SW, Yuan C. Comparison of auscultatory and oscillometric blood pressures. Arch Pediatr Adolesc Med 2001; 155:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/20\">",
"      Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002; 106:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/21\">",
"      Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/22\">",
"      Deal JE, Barratt TM, Dillon MJ. Management of hypertensive emergencies. Arch Dis Child 1992; 67:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/23\">",
"      Flynn JT. Evaluation and management of hypertension in childhood. Prog Pediatr Cardiol 2001; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/24\">",
"      Chandar J, Zilleruelo G. Hypertensive crisis in children. Pediatr Nephrol 2012; 27:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/25\">",
"      Adelman RD. The hypertensive neonate. Clin Perinatol 1988; 15:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17241/abstract/26\">",
"      Arar MY, Hogg RJ, Arant BS Jr, Seikaly MG. Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol 1994; 8:186.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6438 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17241=[""].join("\n");
var outline_f16_53_17241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypertension in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertensive emergency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hypertensive encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Malignant hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypertensive urgency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Symptoms of end organ damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Blood pressure measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Signs of end organ damage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ETIOLOGY OF HYPERTENSIVE EMERGENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Confirm elevated BP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Establish severity of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Exclude other causes of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treat hypertensive emergency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Evaluation for hypertensive emergency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6438|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/22/9582\" title=\"algorithm 1\">",
"      Initial management of children with severe hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6438|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/44/24271\" title=\"figure 1A\">",
"      BP norm birth to 1yr boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/9/21663\" title=\"figure 1B\">",
"      BP norm birth to 1yr girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1025\" title=\"figure 2\">",
"      Determining BP cuff size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6438|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/27/39359\" title=\"picture 1A\">",
"      Grade IV HTN retinopathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/44/19136\" title=\"picture 1B\">",
"      Grade IV HTN retinopathy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/17/32031\" title=\"picture 2\">",
"      Traumatic hemotympanum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/56/16270\" title=\"table 3\">",
"      Neonatal blood pressures and potential treatment parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/60/1997\" title=\"table 4\">",
"      IV medications for pediatric hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/13/14557\" title=\"table 5\">",
"      Rapid overview of hypertensive emergencies in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/40/31372\" title=\"table 6\">",
"      History for hypertensive child or adolescent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/61/34781\" title=\"table 7\">",
"      Pediatric physical findings in hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/49/37659\" title=\"table 8\">",
"      BP cuff sizes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/61/32733\" title=\"table 9\">",
"      Physical findings in the hypertensive child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 10\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/26/11691\" title=\"table 11\">",
"      Laboratory studies for pediatric hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/15/38139\" title=\"table 12\">",
"      Causes of pediatric hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/6/104\" title=\"table 13\">",
"      Pediatric hypertensive emergencies by system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40249?source=related_link\">",
"      Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42105?source=related_link\">",
"      Epidemiology, risk factors, and etiology of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=related_link\">",
"      Etiology, clinical features, and diagnosis of neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41193?source=related_link\">",
"      Group A streptococcus: Virulence factors and pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44630?source=related_link\">",
"      Hypertension in infants between one month and one year of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=related_link\">",
"      Management of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=related_link\">",
"      Management of hypertension in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23065?source=related_link\">",
"      Management of hypertensive emergencies and urgencies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21859?source=related_link\">",
"      Ocular effects of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/570?source=related_link\">",
"      Phencyclidine (PCP) intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17242="Emergency care of moderate and severe thermal burns in adults";
var content_f16_53_17242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency care of moderate and severe thermal burns in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Phillip L Rice, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Dennis P Orgill, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/53/17242/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/53/17242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns are a leading cause of accidental injury and death in the United States (US) and worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Each year approximately one million people in the US seek medical care for burns, approximately one-third of these in the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. Although the vast majority of injuries do not require hospitalization, severe burns can lead to significant morbidity and death.",
"   </p>",
"   <p>",
"    The initial assessment and management of the patient with moderate and severe thermal burns will be reviewed here. Details of burn classification, burn management in children, treatment of minor burns, and other issues related to burn management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34169?source=see_link\">",
"     \"Burn pain: Principles of pharmacologic and nonpharmacologic management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF BURNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Burn Association (ABA) has classified thermal burns into minor, moderate, and major, largely based upon burn depth and size (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57124 \" href=\"UTD.htm?17/7/17532\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73309 \" href=\"UTD.htm?24/50/25381\">",
"     figure 1",
"    </a>",
"    ). The treatment and prognosis of burn victims correlates with this classification. Therefore it is important that clinicians properly characterize the size and severity of their patients' burns. Reassessment of thermal burn size and depth is important, particularly early in the management of patients with severe injuries, as the extent of injury often increases. The classification of burns is reviewed in the tables above and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment and initial treatment of severe burns is performed simultaneously with trauma resuscitation (",
"    <a class=\"graphic graphic_algorithm graphicRef51484 \" href=\"UTD.htm?31/40/32385\">",
"     algorithm 1",
"    </a>",
"    ). Initial management focuses on stabilizing the airway, breathing, and circulation (ABC's). The primary evaluation includes assessing for evidence of respiratory distress and smoke inhalation injury, evaluating cardiovascular status, looking for other injuries, and determining the depth and extent of burns. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification of burns'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hot and burned clothing and debris is removed (caretakers should take precautions to avoid injuring themselves when removing such material). Early transfer to a burn center should be arranged when injuries meet the criteria for major burns (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ). Burn patients may sustain single or multisystem trauma and should be evaluated accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4430737\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paramedics, other victims, or the patient may be able to provide important information such as what burned (eg, chemicals, plastics, textiles), the location of the fire (eg, enclosed or open space), whether an explosion occurred (possibly causing a blast injury), whether the patient used alcohol or drugs, and whether there was associated trauma (eg, from falling debris). The AMPLE trauma history should be obtained, if possible (Allergies, Medications, Past medical history, Last meal, Events).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Assessment and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in ventilatory management, inhalation injury remains a leading cause of death in adult burn victims [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. The risk of inhalation injury increases with the extent of the burn and is present in two-thirds of patients with burns greater than 70 percent of the total body surface area (TBSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/7\">",
"     7",
"    </a>",
"    ]. While assessing the airway, clinicians should immobilize the patient's cervical spine as appropriate.",
"   </p>",
"   <p>",
"    It is critical to maintain the airway and provide supplemental oxygen in patients with major burns [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/8\">",
"     8",
"    </a>",
"    ]. Upper airway edema following a burn-related injury can occur rapidly. Among patients who manifest signs of smoke inhalation, a sizable percentage develop complete airway obstruction and there is no clinical means to determine which patients will do so [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/9\">",
"     9",
"    </a>",
"    ]. Fluid resuscitation can exacerbate laryngeal swelling, increasing the difficulty of tracheal intubation. Therefore, intubation should not be delayed if severe inhalation injury or respiratory distress is present or anticipated. Intubation prior to transport is prudent for many patients who require transfer to a burn center.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    may be used as part of a rapid sequence intubation during the first 72 hours following a severe burn, but not thereafter because of the risk of severe hyperkalemia. A significant percentage of intubated burn patients will develop acute respiratory distress syndrome (ARDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13399?source=see_link\">",
"     \"Emergency airway management in the adult with direct airway trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link&amp;anchor=H4#H4\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\", section on 'Succinylcholine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common signs of significant smoke inhalation injury and the potential need for intubation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent cough, stridor, or wheezing",
"     </li>",
"     <li>",
"      Hoarseness",
"     </li>",
"     <li>",
"      Deep facial or circumferential neck burns",
"     </li>",
"     <li>",
"      Nares with inflammation or singed hair",
"     </li>",
"     <li>",
"      Carbonaceous sputum or burnt matter in the mouth or nose",
"     </li>",
"     <li>",
"      Blistering or edema of the oropharynx",
"     </li>",
"     <li>",
"      Depressed mental status, including evidence of drug or alcohol use",
"     </li>",
"     <li>",
"      Respiratory distress",
"     </li>",
"     <li>",
"      Hypoxia or hypercapnia",
"     </li>",
"     <li>",
"      Elevated carbon monoxide",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cyanide levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Injury from the inhalation of hot gases generally occurs above the vocal cords and can cause significant edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flash burns often harm the face but rarely involve the airway, unlike severe burns from prolonged heat exposure associated with smoke inhalation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diagnostic tests and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initial results may be",
"    <strong>",
"     misleadingly",
"    </strong>",
"    normal, studies to assess pulmonary function should be obtained in patients at risk for inhalation injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/9\">",
"     9",
"    </a>",
"    ]. These include an arterial blood gas (ABG) and a chest x-ray. Serial peak expiratory flow rates (PEFR), if obtainable, in addition to repeat ABGs, can provide evidence of declining pulmonary function, and are particularly useful early in a patient&rsquo;s course. These studies can be repeated whenever findings from repeat examinations, pulse oximetry, or capnography suggest a decline in clinical status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring of end-tidal CO2 (EtCO2) using capnometry or capnography can provide useful information about respiratory status, adequacy of resuscitation, and potential cyanide toxicity, and should be initiated if feasible. A serum lactate concentration should also be obtained if cyanide poisoning is a concern. If available, fiberoptic laryngoscopy and bronchoscopy can assess the extent of airway injury and assist with intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/9\">",
"     9",
"    </a>",
"    ]. An electrocardiogram (ECG) is obtained to asses for cardiac dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Carbon monoxide and cyanide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for carbon monoxide poisoning mandates that a carboxyhemoglobin level be obtained in",
"    <strong>",
"     all",
"    </strong>",
"    patients with moderate or severe burns. Standard pulse oximetry is",
"    <strong>",
"     NOT",
"    </strong>",
"    reliable with significant carbon monoxide toxicity. A standard arterial blood gas reports the concentration of oxygen dissolved in blood and cannot be used to establish or rule out the diagnosis of carbon monoxide or cyanide poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link&amp;anchor=H9#H9\">",
"     \"Carbon monoxide poisoning\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperbaric oxygen treatment may be needed if carbon monoxide levels are high, or if treatment for cyanide poisoning with methemoglobin is necessary but places the patient at risk for severe hypoxemia. Efforts to transport the patient for hyperbaric treatment must not detract from airway management and fluid resuscitation, the most important components of initial burn resuscitation. Treatment with high flow oxygen alone effectively removes carbon monoxide and the benefits of hyperbaric treatment remain a source of controversy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link&amp;anchor=H12#H12\">",
"     \"Carbon monoxide poisoning\", section on 'Hyperbaric oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians should consider the possibility of cyanide toxicity and keep a low threshold for initiating treatment. Complicating the diagnosis is the depressed level of consciousness of many severe burn victims, which may be caused by carbon monoxide, traumatic shock, or head injury, in addition to potential cyanide toxicity. A serum lactate measurement and end-tidal CO2 (EtCO2) monitoring may provide useful information when determining management of these patients and should be performed if cyanide poisoning is a possibility. Cyanide toxicity poisons mitochondria forcing cells to use anaerobic metabolism. This results in a lactic acidosis and a compensatory drop in EtCO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link&amp;anchor=H9#H9\">",
"     \"Cyanide poisoning\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest treatment for cyanide toxicity be initiated in severe burn victims with an unexplained lactic acidosis or a low or declining EtCO2 level. If these measurements are unavailable, we suggest treatment be initiated in any patient demonstrating a depressed level of consciousness, cardiac arrest, or cardiac decompensation. Particularly with severe burn victims, we strongly prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43749?source=see_link\">",
"     hydroxocobalamin",
"    </a>",
"    to alternative cyanide antidotes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link&amp;anchor=H17#H17\">",
"     \"Cyanide poisoning\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen and airway protection are the cornerstones of treatment for inhalation injury. Patients with severe burns often require tracheal intubation. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Assessment and approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bronchodilators (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) can be useful when bronchospasm is present. Corticosteroids, however, have been associated with an increased risk of bacterial infection and should",
"    <strong>",
"     not",
"    </strong>",
"    be used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although fluid resuscitation is critically important in managing patients with significant burns, fluid status should be closely monitored in order to avoid overhydration and possible exacerbation of pulmonary edema. Some researchers have questioned the association between fluid resuscitation volumes and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fluid resuscitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Should mechanical ventilation be necessary, institution of low tidal volume ventilation to minimize airway pressures reduces the incidence of ventilator-associated lung injury and improves outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/11\">",
"     11",
"    </a>",
"    ]. Clinician tolerance of some degree of respiratory acidosis (so-called permissive hypercapnia) may be required to achieve lower airway pressures. Other ventilatory strategies, such as high frequency percussive ventilation and high-frequency oscillatory ventilation may be useful, but are not well studied in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5591?source=see_link\">",
"     \"High-frequency ventilation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatments that may be helpful but need further study include inhaled nitric oxide to treat hypoxic vasoconstriction and aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and N-acetylcysteine (NAC) to remove bronchopulmonary casts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. As an example, in a small single-center, nonrandomized trial, pediatric burn victims with inhalation injury (confirmed by bronchoscopy) treated with aerosolized heparin and NAC experienced reduced reintubation rates, prevalence of atelectasis, and mortality compared with historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fluid resuscitation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Approach to resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn shock during the initial 24 to 48 hours following major burns is characterized by myocardial depression and increased capillary permeability resulting in large fluid shifts and depletion of intravascular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Rapid, aggressive fluid resuscitation to reconstitute intravascular volume and thereby maintain end-organ perfusion is crucial. Delays in fluid resuscitation and inadequate resuscitation are associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Arterial lines are often used to monitor blood pressure; urine output is used to determine the adequacy of fluid resuscitation (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring fluid status'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Over-resuscitation can be problematic and has been associated with multiple morbidities, including acute respiratory distress syndrome, pneumonia, multiorgan failure, and abdominal, extremity, and orbital compartment syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. A survey of burn centers reported that initial fluid resuscitation exceeded recommended amounts in 58 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/11\">",
"     11",
"    </a>",
"    ]. This reinforces the importance of calculating fluid resuscitation needs carefully and of continually adjusting resuscitation efforts according to the physiologic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the American Burn Association's practice guidelines, any patient with greater than 15 percent total body surface area (TBSA) nonsuperficial burns should receive formal fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients with major burns should have two large-bore intravenous (IV) lines placed through unburned skin, if possible, and may require central venous access. IV lines can be placed through burned tissue if necessary to avoid delays in resuscitation. The classification of burns is described in the accompanying figures and discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef73309 \" href=\"UTD.htm?24/50/25381\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57124 \" href=\"UTD.htm?17/7/17532\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255288398\">",
"    <span class=\"h3\">",
"     Fluid selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid resuscitation of the patient with moderate or severe burns consists of an IV crystalloid solution. The ideal solution has not been determined, but lactated Ringer's solution (LR) is typically given; it contains physiologic concentrations of major electrolytes, and lactate may reduce the incidence of hyperchloremic acidosis that may occur with administration of extremely large volumes of isotonic saline (ie, 0.9 percent sodium chloride). Hartmann&rsquo;s solution, another isotonic solution that differs slightly from LR in its concentrations of lactate and electrolytes, is also used. In animal models of burn injury, use of a combined solution of LR and ethyl pyruvate (an oxygen radical scavenger) for resuscitation was associated with increased survival, but this treatment has yet to be studied in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of colloids or hypertonic saline for initial resuscitation is controversial. Colloids (eg, albumin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    ) are significantly more expensive and, according to a meta-analysis of 21 trials involving 1385 critically ill patients, do not improve survival when compared with crystalloids, and are therefore not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/29\">",
"     29",
"    </a>",
"    ]. The use of hypertonic saline as a resuscitation fluid does not appear to provide better outcomes than isotonic solutions and has been associated with increased rates of renal failure and death in one retrospective observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following initial resuscitation efforts, IV fluids are given to meet baseline fluid needs and maintain urine output. Any change to the infusion rate is made as gradually as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/32\">",
"     32",
"    </a>",
"    ]. Should urine output fall below 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour or other clinical parameters suggest inadequate resuscitation, additional fluid is infused. In such a circumstance, a bolus of IV crystalloid (approximately 500 mL to 1000 mL) is given and the infusion of crystalloid increased by approximately 20 to 30 percent. While adequate fluid resuscitation is crucial, care should be taken not to over-resuscitate.",
"   </p>",
"   <p>",
"    If adequate resuscitation has been achieved and the patient is stabilized, the crystalloid solution can be changed to 5 percent dextrose in one-half isotonic saline (ie, 0.45 percent sodium chloride) with 20 mEq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    per liter given at a maintenance rate to keep urine output at or above 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour. Clinicians should continue to monitor the patient's fluid status closely.",
"   </p>",
"   <p>",
"    Enteral resuscitation may be a useful treatment for burn shock patients when intravenous therapy is unavailable, such as with large scale disasters. The World Health Organization (WHO) Oral Rehydration Solution (ORS) has been used successfully to resuscitate animals with 40 percent TBSA burns [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/33\">",
"     33",
"    </a>",
"    ]. No human studies have been performed to validate this approach. Information about how to make ORS can be found on the WHO website (",
"    <a class=\"external\" href=\"file://www.who.int/en/\">",
"     www.who.int/en/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Estimating initial fluid requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;No formula provides a precise method for determining the burn victim's fluid requirements; the formulas described here provide only a starting point and guide to initial fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/34\">",
"     34",
"    </a>",
"    ]. Such factors as patient age, severity of burn, associated injury, and comorbidities can substantially alter the actual fluid requirements of individual patients. As an example, patients with inhalation injury require greater resuscitation volumes than those without [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Therefore, adjustments to estimate fluid needs must be made based upon a burn patient's physiologic response to resuscitation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring fluid status'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Either the Parkland or the modified Brooke formula is a reasonable starting point for determining fluid requirements in adult patients. The Parkland (also known as Baxter) formula is the most widely used guide to initial resuscitation fluid needs in the burn patient, although some studies have questioned its accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. According to this formula, the fluid requirement during the initial 24 hours of treatment is 4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight for each percent of TBSA burned, given IV (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34337?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/19\">",
"     19",
"    </a>",
"    ]. Superficial burns are excluded from this calculation. One-half of the calculated fluid need is given in the first eight hours, and the remaining half is given over the subsequent 16 hours. The rate of infusion for intravenous resuscitation fluid should be as constant as possible; sharp decreases in infusion rates can lead to vascular collapse and an increase in edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One alternative to Parkland is the modified Brooke formula, according to which the fluid requirement during the initial 24 hours of treatment is 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight for each percent of TBSA burned, given IV. According to one retrospective review, use of the modified Brooke formula may reduce the total volume used in fluid resuscitation without causing harm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children require maintenance fluid in addition to calculated fluid resuscitation volumes, and also need dextrose in the resuscitation fluid. The Galveston formula may allow for more accurate calculation of the initial fluid resuscitation children require. It is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergency care of moderate and severe thermal burns in children\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Monitoring fluid status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirming the adequacy of resuscitation is more important than strict adherence to Parkland or any fluid resuscitation formula. Monitoring urine output using an indwelling bladder catheter (eg, Foley catheter) is a readily available means of assessing fluid resuscitation. Hourly urine output should be maintained at 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    in adults. Patients with minimal or no urine output after sustaining severe burns, despite appropriate fluid resuscitation, generally do not survive.",
"   </p>",
"   <p>",
"    Clinical signs of volume status, such as heart rate, blood pressure, pulse pressure, distal pulses, capillary refill, and color and turgor of uninjured skin are monitored every hour for the first 24 hours. Inadequate fluid resuscitation is the most common cause of diminished distal pulses in the newly burned patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential cause of diminished pulses is peripheral edema, which develops in many severe burn patients due to the large fluid volumes needed for resuscitation. As edema increases, elevated compartment pressures can compromise distal circulation and may require escharotomy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Escharotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific laboratory measurements such as mixed venous blood gas and serum lactate concentration are additional important guides to the adequacy of resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/38\">",
"     38",
"    </a>",
"    ]. A decrease in mixed venous oxygen saturation and an increase in serum lactate suggest inadequate end-organ perfusion (elevated serum lactate can also occur with carbon monoxide or cyanide poisoning). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link\">",
"     \"Cyanide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If available, invasive monitoring, such as central venous pressure, may be useful for monitoring fluid resuscitation, but it is generally not used in acute burn management. The American Thoracic Society (ATS) consensus conference report for the detection, correction, and prevention of tissue hypoxia, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Care should be taken not to give excess IV fluid beyond what is needed as this may exacerbate pulmonary edema, a common problem among burn victims. However, some researchers have questioned the association between fluid resuscitation volumes and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New technologies to guide fluid resuscitation are being developed, but require further study before widespread implementation can be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Esophageal echo-Doppler and cardiac output monitoring are being studied with the goal of developing less invasive means of assessing the adequacy of fluid resuscitation in patients with severe burns. Other approaches being studied include Doppler ultrasound measurement of renal perfusion and computer-guided infusions based upon urine output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although evidence is limited, blood transfusions have been associated with increased mortality in patients with severe thermal burns, and we suggest that aggressive transfusion be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. For patients not at significant risk for an acute coronary syndrome (ACS), we suggest transfusing patients with two units of packed red blood cells only if the hemoglobin falls below 8",
"    <span class=\"nowrap\">",
"     g/dL;",
"    </span>",
"    for patients at risk for ACS, we suggest a transfusion threshold of 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Transfusion of the trauma patient with severe hemorrhage is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H3250855#H3250855\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of blood products'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoconcentration occurs during the first several hours immediately following a severe burn and transfusions are generally unnecessary. Thereafter, bone marrow function is depressed and transfusions may be needed. Erythropoietin has not been shown to prevent anemia or decrease transfusion requirements and is not in general use at burn centers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immediate burn care and cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any hot or burned clothing, jewelry, and obvious debris should immediately be removed to prevent further injury and to enable accurate assessment of the extent of burns (caretakers should take precautions to avoid injuring themselves when removing such material).",
"   </p>",
"   <p>",
"    Burned areas should be cooled immediately using cool water or saline soaked gauze. For small and moderate sized burns, cooling can minimize the zone of injury. Multiple studies have investigated optimal burn cooling, with durations from 15 minutes to three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. We generally apply saline-soaked gauzes, at a temperature of approximately 12&ordm;C, for 15 to 30 minutes. Cooling tissue to around 12&ordm;C (54&ordm;F) during the first several hours after injury effectively decreases pain from burns; ice and freezing should be avoided to prevent frostbite, systemic hypothermia, and extension of burn injury.",
"   </p>",
"   <p>",
"    Core body temperature is continuously monitored while cooling is performed to help prevent hypothermia, especially when dealing with burns greater than 10 percent TBSA; body temperature below 35&ordm;C (95&ordm;F) should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Warmed intravenous fluids can be used to maintain core body temperature. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fluid resuscitation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=see_link\">",
"     \"Accidental hypothermia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pain and anxiety management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial-thickness burns in particular can be excruciatingly painful. Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    has been the mainstay of pain management for patients with significant burns. These patients may require",
"    <strong>",
"     extremely large doses",
"    </strong>",
"    of IV morphine or other opioids. It is reasonable to give patients with significant burns benzodiazepines given the anxiety associated with these injuries. The treatment of pain and anxiety in critically ill and burn patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34169?source=see_link\">",
"     \"Burn pain: Principles of pharmacologic and nonpharmacologic management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SECONDARY SURVEY AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the primary survey and initial resuscitation measures are performed, a detailed secondary survey, including a thorough physical examination and the management steps listed below, should be undertaken. Injuries commonly missed in the secondary survey include corneal abrasions and perineal wounds. The secondary survey is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link&amp;anchor=H1929825#H1929825\">",
"     \"Initial management of trauma in adults\", section on 'Secondary evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory studies and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing pulse oximetry and cardiac monitoring are performed for all patients with significant thermal burns. Routine laboratory studies obtained in such patients generally include: complete blood count, electrolytes, blood urea nitrogen, creatinine, glucose, venous blood gas (VBG), and carboxyhemoglobin. Arterial blood gas (ABG), chest radiograph, and an electrocardiogram (ECG) are obtained in any patient at risk for inhalation injury. A cyanide level may be helpful, particularly in the setting of unexplained severe lactic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link\">",
"     \"Cyanide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A blood type and cross-match is obtained for any victim of significant trauma in anticipation of the need for transfusion. Other laboratory studies that may be useful in assessing muscle, cardiac, or end-organ injury include urine myoglobin, serum creatine kinase, and serum lactate. The VBG is a useful tool for assessing shock and the adequacy of resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/52\">",
"     52",
"    </a>",
"    ]. Findings from VBG analysis, including base deficit, correlate with ABGs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extensive burns are considered to be immunosuppressed on the basis of altered neutrophil activity, T lymphocyte dysfunction, and imbalance in the production of cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Bacterial colonization of the burn eschar site can result. The burn also destroys the physical barrier to tissue invasion, which permits spread of the bacteria to the dermis and through the lymphatics along fibrous septae. Once invasion occurs, organisms can proliferate, especially in necrotic tissue, and can invade blood vessels producing a secondary bacteremia. Therefore, prophylaxis against infection with",
"    <strong>",
"     topical",
"    </strong>",
"    antibiotics is given to all patients with nonsuperficial burns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus immunization should be updated if necessary for any burns deeper than superficial-thickness.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     Tetanus immune globulin",
"    </a>",
"    should be given to patients who have not received a complete primary immunization (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antibiotics are applied to all nonsuperficial burns. If the patient is immediately transferred to a burn center, burns are covered with clean, dry dressings and antibiotics are applied at the burn center. Treatment can be started in the ED if, for example, delays in transferring the patient to a burn center are anticipated. The best treatment of blistered burns is unclear. We apply topical antibiotics to partial thickness burns with intact blisters. Topical chemoprophylaxis is typically continued until wound epithelialization is complete. There is no role for prophylactic IV antibiotics.",
"   </p>",
"   <p>",
"    Selection of the topical antibiotic should be made in consultation with the burn center or admitting team, if treatment is begun in the ED. Classically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    (SSD) is used to prevent infection; it should be avoided near the eyes or mouth in those with sulfonamide hypersensitivity and in pregnant women, newborns, and nursing mothers.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     Bacitracin",
"    </a>",
"    is a good alternative topical antibiotic in these individuals. Triple antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ) can also be used. Because of decreased cost, many favor bacitracin. Topical antibiotic treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21593928#H21593928\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Topical antimicrobial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wounds should be cleaned. Embedded bits of clothing or other materials are removed by copious irrigation. Tar and asphalt can be removed with a mixture of cool water and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    &nbsp;but should not be debrided. Copious amounts of polymyxin-B",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    zinc ointment (polysporin) applied for several days will emulsify residual tar. Management of tar and asphalt is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=see_link&amp;anchor=H28#H28\">",
"     \"Topical chemical burns\", section on 'Tar and asphalt'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some providers clean burns using skin disinfectants (eg, Hibiclens, Betadine), but such disinfectants can inhibit the healing process and are discouraged. There is growing support for washing the wound using only mild soap and water [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/2,58-61\">",
"     2,58-61",
"    </a>",
"    ]. The cleaning and debridement of burn wounds are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21593921#H21593921\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Cleansing and debridement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to IV opioids, local or regional anesthesia can be used prior to wound care in patients with excruciating pain. However, injection directly into the wound or topical application should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pain and anxiety management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ruptured blisters should be removed, but the management of clean, intact blisters is controversial. Needle aspiration of blisters should",
"    <strong>",
"     never",
"    </strong>",
"    be performed as this increases the risk of infection. Burn blisters are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H1054478388#H1054478388\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Burn blisters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Wound dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients rapidly transferred to a burn center can be wrapped in a clean dry sheet and do not require any additional dressing. Otherwise, all partial and full-thickness burns should have dressings.",
"   </p>",
"   <p>",
"    A fine, nonadherent, mesh gauze (eg, Telfa&reg;) typically is applied, after the burn is cleansed and a thin layer of topical antibiotic is applied. Circulatory impairment is minimized by applying this nonadherent dressing in successive strips rather than wrapping it around the wound [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/62\">",
"     62",
"    </a>",
"    ]. The dressing is held in place using either a tubular net bandage or gauze wraps lightly applied. The following video clips show a basic burn dressing being applied in the operating room: (",
"    <a class=\"graphic graphic_movie graphicRef86906 \" href=\"UTD.htm?22/9/22676\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Deep wounds may require biologic or biosynthetic dressings or bismuth-impregnated petroleum gauze. Burn dressings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21593997#H21593997\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Dressings'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Escharotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escharotomy of the neck or chest may be required if mechanical constriction from eschar prevents adequate respiration. Ideally, escharotomy is performed by an experienced clinician to avoid damage to underlying structures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/19,63\">",
"     19,63",
"    </a>",
"    ]. Drawings showing the approximate lines of incision are provided in the rare event that escharotomies must be performed in the ED (",
"    <a class=\"graphic graphic_figure graphicRef79668 \" href=\"UTD.htm?15/6/15457\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63976 \" href=\"UTD.htm?41/57/42911\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Decompressive escharotomy of an extremity may be required for circumferential full-thickness burns, if edema causes constriction and distal ischemia (",
"    <a class=\"graphic graphic_picture graphicRef86905 \" href=\"UTD.htm?19/38/20064\">",
"     picture 1",
"    </a>",
"    ). Although a number of parameters exist to guide the timing of escharotomies, most often the decision is made clinically based on the presence of constrictive wounds and compromised distal perfusion. Constrictive swelling does not occur until fluid resuscitation is underway and escharotomy is rarely required in the immediate aftermath of a burn.",
"   </p>",
"   <p>",
"    Distal tissue compartment pressures ranging from 25 to 40 mmHg have been used as the threshold to perform escharotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/19\">",
"     19",
"    </a>",
"    ], while a tissue pressure within 30 mmHg of the diastolic blood pressure is the threshold preferred by others. A Doppler flowmeter is optimal for ongoing assessment of whether elevated compartment pressures have compromised the perfusion of a burned extremity. Clinicians should keep in mind the distinction between escharotomy, an incision through the eschar only, and fasciotomy, which involves incisions through all involved fascial layers to treat acute compartment syndrome of the extremities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link\">",
"     \"Lower extremity fasciotomy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gastrointestinal interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock from thermal burn injuries results in mesenteric vasoconstriction predisposing to gastric distension, ulceration (so-called Curling's ulcer), and aspiration. Therefore, a nasogastric tube should be placed in patients with moderate or severe burns &gt;20 percent TBSA [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/22\">",
"     22",
"    </a>",
"    ]. High-risk patients receive medication to reduce gastric acid secretion, but this is usually initiated after admission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally not begun in the emergency department, early enteral feedings (ie, within 24 hours of injury) to meet basic patient energy needs attenuate the catabolic response to burns and are associated with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/19,64,65\">",
"     19,64,65",
"    </a>",
"    ]. Overfeeding does not help to maintain lean body mass and is associated with fatty liver so is to be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Modulating the catabolic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major burns cause a hypermetabolic state that is associated with a number of harmful physiologic derangements including immunosuppression, impaired wound healing, muscle catabolism, and hepatic dysfunction. A number of treatments are used to attenuate this hypermetabolic state. These treatments are generally initiated in the intensive care unit but may be started in the emergency department in close coordination with the burn team that will be assuming care of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who meet the American Burn Association's (ABA) criteria for major burns should be transferred to a burn center (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ). Patients with moderate burns should be admitted for intravenous hydration and surgical care of their wounds.",
"   </p>",
"   <p>",
"    Because of the initial difficulties in differentiating deep partial-thickness burns from full-thickness burns, clinicians should have a low threshold for consulting surgery for any patient with what appears to be a deep partial-thickness burn affecting more than 3 percent TBSA (total percentage of body surface area). An algorithm assisting with identifying and managing ambulatory burn patients is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef51484 \" href=\"UTD.htm?31/40/32385\">",
"     algorithm 1",
"    </a>",
"    ). General guidelines for hospitalization include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Admit patients suspected of inhalation injury for observation; fiberoptic bronchoscopy or xenon ventilation perfusion scanning is useful if the diagnosis is in doubt [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/7,48,67,68\">",
"       7,48,67,68",
"      </a>",
"      ]. Pulmonary dysfunction causes more than 75 percent of fire-related deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/1,4,5\">",
"       1,4,5",
"      </a>",
"      ].",
"      <strong>",
"       Initial evaluations may be normal",
"      </strong>",
"      in patients with inhalation injury who subsequently develop severe respiratory distress. Check for carbon monoxide poisoning; treatment with hyperbaric oxygen may be necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/69\">",
"       69",
"      </a>",
"      ]. Consider cyanide poisoning and provide presumptive treatment when indicated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Airway management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Carbon monoxide and cyanide'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"       \"Smoke inhalation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Admit patients with moderate to severe burns (",
"      <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Admit patients with circumferential partial or full-thickness burns.",
"     </li>",
"     <li>",
"      Patients at greater risk for development of infection of nonsuperficial wounds, such as diabetics and the elderly, generally should be hospitalized.",
"     </li>",
"     <li>",
"      Patients with a high voltage injury who have an abnormal electrocardiogram (nonspecific ST-T wave changes most commonly) are at increased risk for cardiac arrhythmias and should be observed until the ECG normalizes [",
"      <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/48,59\">",
"       48,59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=see_link\">",
"       \"Environmental electrical injuries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MORTALITY AND ETHICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chance of survival after a severe burn increased steadily in the second half of the 20th century due to a number of therapeutic developments, including vigorous fluid resuscitation, early excision of burn wounds, advances in critical care and nutrition, topical antibiotic use, and the evolution of specialized burn centers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/70\">",
"     70",
"    </a>",
"    ]. Even among patients hospitalized for burns, survival exceeds 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have investigated the variables associated with increased mortality in burn patients. In one retrospective review of 1665 patients admitted to a tertiary care hospital (mean burn size 14 &plusmn;20 percent TBSA, mean age 21&plusmn; 20 years), three risk factors for death were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age greater than 60 years",
"     </li>",
"     <li>",
"      Nonsuperficial burns covering over 40 percent TBSA",
"     </li>",
"     <li>",
"      Inhalation injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors developed a mortality formula that predicts a 0.3, 3, 33, or 90 percent mortality depending upon whether zero, one, two, or three risk factors are present.",
"   </p>",
"   <p>",
"    This study was criticized for having too few patients with three risk factors to make an accurate mortality estimate, and for having a high incidence of do not resuscitate orders among the sicker patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/70\">",
"     70",
"    </a>",
"    ]. In addition, mortality estimates by others who used this model have not coincided with those predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/73\">",
"     73",
"    </a>",
"    ]. Nevertheless, the formula appears to provide a reasonable approximation of the risk of death in patients with severe burns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Patient autonomy and aggressiveness of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although well beyond the scope of this review, the issue of patient autonomy in the setting of severe thermal injury warrants mention. Victims of severe burns face a prolonged, frequently painful period of treatment, during much of which their ability to communicate their desires will be impaired by the effects of and treatments for their injuries. Therefore, at the start of their initial resuscitation, during which many patients are lucid, it is reasonable to ask what types of care they wish and do not wish to receive [",
"    <a class=\"abstract\" href=\"UTD.htm?16/53/17242/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19477?source=see_link\">",
"     \"Ethical considerations in effective pain management at the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe thermal burns are at significant risk of death and major morbidity. Proper management during their initial resuscitation reduces such risk (",
"    <a class=\"graphic graphic_algorithm graphicRef51484 \" href=\"UTD.htm?31/40/32385\">",
"     algorithm 1",
"    </a>",
"    ). Below are listed critical points in the initial management of patients with severe thermal injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway, breathing, and circulation &ndash; Perform a primary trauma survey with appropriate management (",
"      <a class=\"graphic graphic_algorithm graphicRef51484 \" href=\"UTD.htm?31/40/32385\">",
"       algorithm 1",
"      </a>",
"      ). Look for evidence of respiratory distress and smoke inhalation injury, a common cause of death in the acute burn victim. Initial assessment may reveal no evidence of injury, but laryngeal edema can develop suddenly and unexpectedly. Aggressive airway management with early intubation is warranted if there is evidence of inhalation injury. Signs and symptoms of inhalation injury are described above. Obtain a chest x-ray, arterial blood gas, and electrocardiogram in all patients at risk for respiratory problems. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Airway management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Laboratory studies and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burn depth and size determine fluid resuscitation and the need for transfer (",
"      <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"       table 1",
"      </a>",
"      ). They must be accurately assessed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"       \"Classification of burns\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Burn shock &ndash; Vascular collapse from burn shock is a critical component of the pathophysiologic response to severe burns. Rapid, aggressive fluid resuscitation to reconstitute intravascular volume and maintain end-organ perfusion is crucial. Fluid requirements are based initially upon a formula (eg, Parkland) and subsequently upon",
"      <strong>",
"       patient response",
"      </strong>",
"      to the initial IV fluids. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fluid resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial, estimated fluid requirements &ndash; We suggest using lactated ringers for fluid resuscitation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The Parkland-Baxter formula can be used to calculate initial fluid needs. According to this formula, the fluid requirement during the initial 24 hours of treatment is 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of body weight for each percent of TBSA burned, given IV (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34337?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). Superficial burns are excluded from this calculation. One-half of the calculated fluid need is given in the first eight hours, and the remaining half is given over the subsequent 16 hours. The rate of infusion for IV resuscitation fluid should be as constant as possible; rapid declines in infusion rates can lead to vascular collapse and an increase in edema. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Estimating initial fluid requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring fluid status &ndash; Monitor urine output using an indwelling bladder catheter (eg, Foley catheter). Hourly urine output should be maintained at 0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in adults. Clinical signs of volume status, such as heart rate, blood pressure, pulse pressure, distal pulses, capillary refill, and color and turgor of uninjured skin are monitored every hour for the first 24 hours. Inadequate fluid resuscitation is the most common cause of diminished distal pulses in the newly burned patient. A decrease in mixed venous oxygen saturation and an increase in serum lactate suggest inadequate end-organ perfusion. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring fluid status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carbon monoxide and cyanide &ndash; Burn patients may be exposed to carbon monoxide, requiring immediate treatment with high-flow oxygen (and possibly hyperbaric oxygen), and cyanide, requiring antidotal therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Carbon monoxide and cyanide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound care &ndash; Cool and clean wounds, but avoid inducing hypothermia in this process. Mild soap and water is suitable. Monitor the patient's core temperature continually. Remove any jewelry and any hot or burned clothing and obvious debris not densely adherent to the skin. Irrigation with cool water may be used.",
"      <strong>",
"       Topical",
"      </strong>",
"      antibiotics are applied to all nonsuperficial burns. If the patient is immediately transferred to a burn center, burns are covered with clean, dry dressings and antibiotics are applied at the burn center. There is no role for prophylactic IV antibiotics. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Wound management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain control and additional interventions &ndash; Give opioids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ) to treat pain and give tetanus prophylaxis. Extremely high doses of opioids may be required. Benzodiazepines can help relieve anxiety. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chemoprophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coordination with burn team &ndash; Emergency clinicians should coordinate patient care closely with either the admitting or, in the case of transfer, with the accepting burn team. A number of additional medications may be of benefit, but most are begun after the patient has left the emergency department (ED). We institute glycemic control using an insulin drip as early as possible. Additional treatments to minimize the catabolic response should be initiated in close consultation with the burn team that will assume care of the patient. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Modulating the catabolic response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Gastrointestinal interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2424166\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/1\">",
"      Brigham PA, McLoughlin E. Burn incidence and medical care use in the United States: estimates, trends, and data sources. J Burn Care Rehabil 1996; 17:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/2\">",
"      Mertens DM, Jenkins ME, Warden GD. Outpatient burn management. Nurs Clin North Am 1997; 32:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/3\">",
"      Wasiak J, Spinks A, Ashby K, et al. The epidemiology of burn injuries in an Australian setting, 2000-2006. Burns 2009; 35:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/4\">",
"      Gomez R, Murray CK, Hospenthal DR, et al. Causes of mortality by autopsy findings of combat casualties and civilian patients admitted to a burn unit. J Am Coll Surg 2009; 208:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/5\">",
"      Bloemsma GC, Dokter J, Boxma H, Oen IM. Mortality and causes of death in a burn centre. Burns 2008; 34:1103.",
"     </a>",
"    </li>",
"    <li>",
"     www.ameriburn.org/resources_factsheet.php (Accessed on September 02, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/7\">",
"      Monafo WW. Initial management of burns. N Engl J Med 1996; 335:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/8\">",
"      Cancio LC. Airway management and smoke inhalation injury in the burn patient. Clin Plast Surg 2009; 36:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/9\">",
"      Miller K, Chang A. Acute inhalation injury. Emerg Med Clin North Am 2003; 21:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/10\">",
"      Holm C, Tegeler J, Mayr M, et al. Effect of crystalloid resuscitation and inhalation injury on extravascular lung water: clinical implications. Chest 2002; 121:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/11\">",
"      Ipaktchi K, Arbabi S. Advances in burn critical care. Crit Care Med 2006; 34:S239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/12\">",
"      Cioffi WG Jr, Rue LW 3rd, Graves TA, et al. Prophylactic use of high-frequency percussive ventilation in patients with inhalation injury. Ann Surg 1991; 213:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/13\">",
"      Cartotto R, Ellis S, Smith T. Use of high-frequency oscillatory ventilation in burn patients. Crit Care Med 2005; 33:S175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/14\">",
"      Chung KK, Wolf SE, Renz EM, et al. High-frequency percussive ventilation and low tidal volume ventilation in burns: a randomized controlled trial. Crit Care Med 2010; 38:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/15\">",
"      Sheridan RL, Hurford WE, Kacmarek RM, et al. Inhaled nitric oxide in burn patients with respiratory failure. J Trauma 1997; 42:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/16\">",
"      Desai MH, Mlcak R, Richardson J, et al. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy. J Burn Care Rehabil 1998; 19:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/17\">",
"      Toon MH, Maybauer MO, Greenwood JE, et al. Management of acute smoke inhalation injury. Crit Care Resusc 2010; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/18\">",
"      Murakami K, McGuire R, Cox RA, et al. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002; 18:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/19\">",
"      Saffle, JR. Practice guidelines for burn care. J Burn Care 2001; 22(Suppl):i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/20\">",
"      Hettiaratchy S, Dziewulski P. ABC of burns: pathophysiology and types of burns. BMJ 2004; 328:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/21\">",
"      Evers LH, Bhavsar D, Mail&auml;nder P. The biology of burn injury. Exp Dermatol 2010; 19:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/22\">",
"      Ramzy PI, Barret JP, Herndon DN. Thermal injury. Crit Care Clin 1999; 15:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/23\">",
"      Wolf SE, Rose JK, Desai MH, et al. Mortality determinants in massive pediatric burns. An analysis of 103 children with &gt; or = 80% TBSA burns (&gt; or = 70% full-thickness). Ann Surg 1997; 225:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/24\">",
"      Holm C, Melcer B, H&ouml;rbrand F, et al. The relationship between oxygen delivery and oxygen consumption during fluid resuscitation of burn-related shock. J Burn Care Rehabil 2000; 21:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/25\">",
"      Klein MB, Hayden D, Elson C, et al. The association between fluid administration and outcome following major burn: a multicenter study. Ann Surg 2007; 245:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/26\">",
"      Dulhunty JM, Boots RJ, Rudd MJ, et al. Increased fluid resuscitation can lead to adverse outcomes in major-burn injured patients, but low mortality is achievable. Burns 2008; 34:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/27\">",
"      Sullivan SR, Ahmadi AJ, Singh CN, et al. Elevated orbital pressure: another untoward effect of massive resuscitation after burn injury. J Trauma 2006; 60:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/28\">",
"      Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol 2008; 21:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/29\">",
"      Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2012; 6:CD000567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/30\">",
"      Bunn F, Roberts I, Tasker R, Akpa E. Hypertonic versus near isotonic crystalloid for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004; :CD002045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/31\">",
"      Huang PP, Stucky FS, Dimick AR, et al. Hypertonic sodium resuscitation is associated with renal failure and death. Ann Surg 1995; 221:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/32\">",
"      Gueugniaud PY, Carsin H, Bertin-Maghit M, Petit P. Current advances in the initial management of major thermal burns. Intensive Care Med 2000; 26:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/33\">",
"      Michell MW, Oliveira HM, Kinsky MP, et al. Enteral resuscitation of burn shock using World Health Organization oral rehydration solution: a potential solution for mass casualty care. J Burn Care Res 2006; 27:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/34\">",
"      Blumetti J, Hunt JL, Arnoldo BD, et al. The Parkland formula under fire: is the criticism justified? J Burn Care Res 2008; 29:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/35\">",
"      Dai NT, Chen TM, Cheng TY, et al. The comparison of early fluid therapy in extensive flame burns between inhalation and noninhalation injuries. Burns 1998; 24:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/36\">",
"      Navar PD, Saffle JR, Warden GD. Effect of inhalation injury on fluid resuscitation requirements after thermal injury. Am J Surg 1985; 150:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/37\">",
"      Holm C, Mayr M, Tegeler J, et al. A clinical randomized study on the effects of invasive monitoring on burn shock resuscitation. Burns 2004; 30:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/38\">",
"      Holm C, Melcer B, H&ouml;rbrand F, et al. Haemodynamic and oxygen transport responses in survivors and non-survivors following thermal injury. Burns 2000; 26:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/39\">",
"      Chung KK, Wolf SE, Cancio LC, et al. Resuscitation of severely burned military casualties: fluid begets more fluid. J Trauma 2009; 67:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/40\">",
"      Namias N. Advances in burn care. Curr Opin Crit Care 2007; 13:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/41\">",
"      Wang GY, Ma B, Tang HT, et al. Esophageal echo-Doppler monitoring in burn shock resuscitation: are hemodynamic variables the critical standard guiding fluid therapy? J Trauma 2008; 65:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/42\">",
"      Reid RD, Jayamaha J. The use of a cardiac output monitor to guide the initial fluid resuscitation in a patient with burns. Emerg Med J 2007; 24:e32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/43\">",
"      Salinas J, Chung KK, Mann EA, et al. Computerized decision support system improves fluid resuscitation following severe burns: an original study. Crit Care Med 2011; 39:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/44\">",
"      Kwan P, Gomez M, Cartotto R. Safe and successful restriction of transfusion in burn patients. J Burn Care Res 2006; 27:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/45\">",
"      Palmieri TL, Caruso DM, Foster KN, et al. Effect of blood transfusion on outcome after major burn injury: a multicenter study. Crit Care Med 2006; 34:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/46\">",
"      Higgins S, Fowler R, Callum J, Cartotto R. Transfusion-related acute lung injury in patients with burns. J Burn Care Res 2007; 28:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/47\">",
"      Pushkar NS, Sandorminsky BP. Cold treatment of burns. Burns Incl Therm Inj 1982; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     Hartford, CE. Care of outpatient burns. In: Total Burn Care, Herndon, D (Eds), WB Saunders, Philadelphia 1996. p.71.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/49\">",
"      Allwood JS. The primary care management of burns. Nurse Pract 1995; 20:74, 77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/50\">",
"      Purdue GF, Layton TR, Copeland CE. Cold injury complicating burn therapy. J Trauma 1985; 25:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/51\">",
"      Singer AJ, Taira BR, Thode HC Jr, et al. The association between hypothermia, prehospital cooling, and mortality in burn victims. Acad Emerg Med 2010; 17:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/52\">",
"      Baron BJ, Barrett D, Stavile KL, et al. Correlation of arterial and venous base deficits during the initial assessment of trauma patients [abstract]. Acad Emerg Med 2000; 7:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/53\">",
"      Evron S, Tress V, Ezri T, et al. The importance of blood sampling site for determination of hemoglobin and biochemistry values in major abdominal and orthopedic surgery. J Clin Anesth 2007; 19:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/54\">",
"      Bjerknes R, Vindenes H, Laerum OD. Altered neutrophil functions in patients with large burns. Blood Cells 1990; 16:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/55\">",
"      Schwacha MG, Ayala A, Chaudry IH. Insights into the role of gammadelta T lymphocytes in the immunopathogenic response to thermal injury. J Leukoc Biol 2000; 67:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/56\">",
"      Peter FW, Schuschke DA, Barker JH, et al. The effect of severe burn injury on proinflammatory cytokines and leukocyte behavior: its modulation with granulocyte colony-stimulating factor. Burns 1999; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/57\">",
"      Karyoute SM, Badran IZ. Tetanus following a burn injury. Burns Incl Therm Inj 1988; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/58\">",
"      Baxter CR. Management of burn wounds. Dermatol Clin 1993; 11:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/59\">",
"      Waitzman AA, Neligan PC. How to manage burns in primary care. Can Fam Physician 1993; 39:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/60\">",
"      Hill MG, Bowen CC. The treatment of minor burns in rural Alabama emergency departments. J Emerg Nurs 1996; 22:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/61\">",
"      Greenhalgh DG. The healing of burn wounds. Dermatol Nurs 1996; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/62\">",
"      Martinez S. Ambulatory management of burns in children. J Pediatr Health Care 1992; 6:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/63\">",
"      Orgill DP, Piccolo N. Escharotomy and decompressive therapies in burns. J Burn Care Res 2009; 30:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/64\">",
"      Mosier MJ, Pham TN, Klein MB, et al. Early enteral nutrition in burns: compliance with guidelines and associated outcomes in a multicenter study. J Burn Care Res 2011; 32:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/65\">",
"      Wasiak J, Cleland H, Jeffery R. Early versus late enteral nutritional support in adults with burn injury: a systematic review. J Hum Nutr Diet 2007; 20:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/66\">",
"      Hart DW, Wolf SE, Herndon DN, et al. Energy expenditure and caloric balance after burn: increased feeding leads to fat rather than lean mass accretion. Ann Surg 2002; 235:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/67\">",
"      Peate WF. Outpatient management of burns. Am Fam Physician 1992; 45:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/68\">",
"      Moylan JA. Supportive therapy in burn care. Smoke inhalation. Diagnostic techniques and steroids. J Trauma 1979; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/69\">",
"      Heimbach DM, Waeckerle JF. Inhalation injuries. Ann Emerg Med 1988; 17:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/70\">",
"      Saffle JR. Predicting outcomes of burns. N Engl J Med 1998; 338:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/71\">",
"      Ryan CM, Schoenfeld DA, Thorpe WP, et al. Objective estimates of the probability of death from burn injuries. N Engl J Med 1998; 338:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/72\">",
"      Saffle JR, Davis B, Williams P. Recent outcomes in the treatment of burn injury in the United States: a report from the American Burn Association Patient Registry. J Burn Care Rehabil 1995; 16:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/73\">",
"      Choini&egrave;re M, Dumont M, Papillon J, Garrel DR. Prediction of death in patients with burns. Lancet 1999; 353:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/53/17242/abstract/74\">",
"      Imbus SH, Zawacki BE. Autonomy for burned patients when survival is unprecedented. N Engl J Med 1977; 297:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 350 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17242=[""].join("\n");
var outline_f16_53_17242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF BURNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL ASSESSMENT AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4430737\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Assessment and approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diagnostic tests and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Carbon monoxide and cyanide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Approach to resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H255288398\">",
"      - Fluid selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Estimating initial fluid requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Monitoring fluid status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immediate burn care and cooling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pain and anxiety management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SECONDARY SURVEY AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory studies and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Tetanus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Wound dressings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Escharotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gastrointestinal interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Modulating the catabolic response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MORTALITY AND ETHICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Patient autonomy and aggressiveness of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2424166\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/350|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/40/32385\" title=\"algorithm 1\">",
"      Initial burn management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/350|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/50/25381\" title=\"figure 1\">",
"      Burn class depth skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/6/15457\" title=\"figure 2\">",
"      Chest escharotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/57/42911\" title=\"figure 3\">",
"      Schematic for incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/350|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/38/20064\" title=\"picture 1\">",
"      Lower extremity escharotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/350|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/9/22676\" title=\"movie 1\">",
"      Application of a basic burn dressing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2268\" title=\"table 1\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17532\" title=\"table 2\">",
"      Burn depth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 3\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34337?source=related_link\" title=\"calculator 1\">",
"      Calculator: Adult burn injury fluid resuscitation (Parkland crystalloid estimate)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15913?source=related_link\">",
"      Accidental hypothermia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34169?source=related_link\">",
"      Burn pain: Principles of pharmacologic and nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=related_link\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13399?source=related_link\">",
"      Emergency airway management in the adult with direct airway trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19477?source=related_link\">",
"      Ethical considerations in effective pain management at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5591?source=related_link\">",
"      High-frequency ventilation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=related_link\">",
"      Lower extremity fasciotomy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11801?source=related_link\">",
"      Topical chemical burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_53_17243="Psychosomatic abdominal pain criteria";
var content_f16_53_17243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for the diagnosis of psychosomatic recurrent abdominal pain* in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Organic disorders must be excluded, and at least six of the following seven criteria must be satisfied:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Onset or aggravation of chronic negative stress at the time of onset of recurrent pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Pain parallels chronic negative stress",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Better or pain-free during periods of lessened/disappeared chronic negative stress",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Acute stress induces pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Most pain attacks related to acute stress",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. The child followed up for at least one year",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Parents/child and responsible doctor agree about the diagnosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Recurrent abdominal pain: At least three episodes of recurrent abdominal pain severe enough to affect the child's activities over a period of more than three months.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Alfven G. One hundred cases of recurrent abdominal pain in children: diagnostic procedure and criteria for psychosomatic diagnosis. Acta Paediatr 2003; 92:43.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17243=[""].join("\n");
var outline_f16_53_17243=null;
var title_f16_53_17244="Causes of goiter in adults";
var content_f16_53_17244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of goiter in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Multinodular goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodine-deficiency goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Autoimmune/thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic autoimmune (Hashimoto's) thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Painless thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subacute thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postpartum thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infectious thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ingestion of goitrogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iodine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lithium carbonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Foodstuffs (cassava, millet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid infiltrative disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Riedel's thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amyloid goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cystinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Toxic goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Graves' disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autonomously functioning thyroid adenoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thyroglossal duct cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid adenomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Thyroid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Papillary carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Follicular carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Medullary carcinoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17244=[""].join("\n");
var outline_f16_53_17244=null;
var title_f16_53_17245="Aggressive BP reduction in CRF";
var content_f16_53_17245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aggressive BP control preserves renal function in proteinuric patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean fall in glomerular filtration rate (GFR) according to the degree of proteiuria in patients treated with usual blood pressure control (mean BP about 130/80) or with more aggressive antihypertensive therapy in which the mean BP was 4.7 mmHg lower over a three year period. The rate of fall in GFR varied directly with protein excretion and the benefit of aggressive BP control was absent in the 420 patients excreting less than 1 g/day, modest in the 104 patients excreting between 1 and 3 g/day, and substantial (3.5 mL/min per year slower) and statistically significant in the 54 patients excreting at least 3 g/day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Klahr S, Levey AS, Beck GJ, et al. N Engl J Med 1994; 330:877.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17245=[""].join("\n");
var outline_f16_53_17245=null;
var title_f16_53_17246="Modified FOLFOX6";
var content_f16_53_17246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified FOLFOX6 chemotherapy for gastrointestinal cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV*",
"       </td>",
"       <td>",
"        Dilute with 250 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        400",
"        <sup>",
"         &sect;",
"        </sup>",
"        mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL D5W",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over two hours concurrent with oxaliplatin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV bolus",
"       </td>",
"       <td>",
"        Slow IV push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         <strong>",
"          Fluorouracil (FU)",
"         </strong>",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin and FU are classified as irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &lt;5 percent",
"        <sup>",
"         [2]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of oxaliplatin may be needed for severe renal impairment",
"        <sup>",
"         [3]",
"        </sup>",
"        . A lower starting dose of FU may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during, and for approximately 48 hours after each infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment cycle by one week for total white blood cell count &lt;3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , absolute neutrophil count &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or platelets &lt;100,000 /mm",
"        <sup>",
"         3",
"        </sup>",
"        on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate FU bolus. With the second occurrence, reduce infusional FU by 20 percent and reduce oxaliplatin dose from 85 to 65 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 25 percent. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment for grade 2 or worse diarrhea, and restart at a lower dose of FU after complete resolution",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [5]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"     <br/>",
"     &sect; The dose of leucovorin in the two trials of modified FOLFOX6 was 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . However, most clinicians use the standard 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     doses as was used for original FOLFOX6",
"     <sup>",
"      [6]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cheeseman SL, et al. Br J Cancer 2002; 87:393.",
"      </li>",
"      <li>",
"       Hochster HS, et al. J Clin Oncol 2008; 26:3523.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Tournigand C, et al. J Clin Oncol 2004; 22:229.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17246=[""].join("\n");
var outline_f16_53_17246=null;
var title_f16_53_17247="Moderate VUR on nuclear cystogram";
var content_f16_53_17247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nuclear cystogram demonstrating moderate vesicoureteral reflux",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_53_17247=[""].join("\n");
var outline_f16_53_17247=null;
